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Next-Generation Oligonucleotide Probes For Transcriptome In Vivo Analysis (tiva)
Abstract
The transcriptome ‒ the total collection of every RNA transcript in a cell ‒ provides a unique readout of a
cell’s commands as it executes its own genetic code. Studying the transcriptomes of individual cells is a
powerful way to identify new cell types, building a better understanding of complex tissues from the
ground up. Furthermore, transcriptomic characterization of tumor samples is already leading to tangible
advancements in personalized cancer care. However, the process of capturing a transcriptome requires
careful isolation of mRNA from a single cell that is potentially entrenched in an entangled, threedimensional tissue structure.
Our lab has previously developed a method to successfully isolate mRNA from single cells still
contextualized within living tissue. This method, Transcriptome In Vivo Analysis (TIVA), utilizes a lightactivatable oligonucleotide probe to offer fine spatio-temporal control of mRNA capture. TIVA probes are
highly modified RNA hairpins or loops incorporating a poly(U) “capture” sequence complementary to the
poly(A) tail of mRNA, as well as a biotin moiety to enable pull-down of bound mRNA. To enable spatiotemporal control of mRNA binding, the probes are locked into an inactive “caged” conformation. Laser
excitation of the target cell severs photoactivable o-nitrobenzyl- or Ru(II) polypyridyl-based linkages built
into the probe, freeing the poly(U) capture sequence to effectively biotinylate mRNA. After photolysis, a
small tissue region containing the target cell is aspirated out and lysed so that the target mRNA can be
isolated by streptavidin-biotin affinity purification.
In this dissertation I present the synthesis, characterization, and application of next-generation TIVA
constructs that aim to address various limitations of the original probe. (I) I demonstrate that
phosphorothioation extends the serum stability of the TIVA probe from a few minutes to over 24 hours,
and mediates uptake into cells without the need for a cell-penetrating peptide. (II) I also present versions
of the probe with hairpin-terminating GC pairs, longer blocking strands, and a pegylated hairpin turn which
dramatically reduce the probe’s pre-photolysis background binding of mRNA. (III) Finally, I show that
incorporation of a Ru(II) polypyridyl-based photocleavable linker extends the probe’s activation response
from 1-photon near-UV light to 2-photon near-IR light. Together, these advancements move TIVA towards
a broader range of applications – including deeper regions of challenging, nuclease-abundant tissues –
with greater confidence that our construct will remain stable and generate a low-background
transcriptome.
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ABSTRACT
NEXT-GENERATION OLIGONUCLEOTIDE PROBES FOR TRANSCRIPTOME IN VIVO
ANALYSIS (TIVA)
Sean B. Yeldell
Ivan J. Dmochowski

The transcriptome ‒ the total collection of every RNA transcript in a cell ‒ provides a
unique readout of a cell’s commands as it executes its own genetic code. Studying the
transcriptomes of individual cells is a powerful way to identify new cell types, building a better
understanding

of

complex

tissues

from

the

ground

up.

Furthermore,

transcriptomic

characterization of tumor samples is already leading to tangible advancements in personalized
cancer care. However, the process of capturing a transcriptome requires careful isolation of
mRNA from a single cell that is potentially entrenched in an entangled, three-dimensional tissue
structure.
Our lab has previously developed a method to successfully isolate mRNA from single
cells still contextualized within living tissue. This method, Transcriptome In Vivo Analysis (TIVA),
utilizes a light-activatable oligonucleotide probe to offer fine spatio-temporal control of mRNA
capture. TIVA probes are highly modified RNA hairpins or loops incorporating a poly(U) “capture”
sequence complementary to the poly(A) tail of mRNA, as well as a biotin moiety to enable pulldown of bound mRNA. To enable spatio-temporal control of mRNA binding, the probes are
locked into an inactive “caged” conformation. Laser excitation of the target cell severs
photoactivable o-nitrobenzyl- or Ru(II) polypyridyl-based linkages built into the probe, freeing the
poly(U) capture sequence to effectively biotinylate mRNA. After photolysis, a small tissue region
containing the target cell is aspirated out and lysed so that the target mRNA can be isolated by
streptavidin-biotin affinity purification.
In this dissertation I present the synthesis, characterization, and application of nextgeneration TIVA constructs that aim to address various limitations of the original probe. (I) I
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demonstrate that phosphorothioation extends the serum stability of the TIVA probe from a few
minutes to over 24 hours, and mediates uptake into cells without the need for a cell-penetrating
peptide. (II) I also present versions of the probe with hairpin-terminating GC pairs, longer blocking
strands, and a pegylated hairpin turn which dramatically reduce the probe’s pre-photolysis
background binding of mRNA. (III) Finally, I show that incorporation of a Ru(II) polypyridyl-based
photocleavable linker extends the probe’s activation response from 1-photon near-UV light to 2photon near-IR light. Together, these advancements move TIVA towards a broader range of
applications – including deeper regions of challenging, nuclease-abundant tissues – with greater
confidence that our construct will remain stable and generate a low-background transcriptome.
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Chapter One
An introduction to transcriptomics and light-activatable oligonucleotides
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INTRODUCTION PART 1: THE TRANSCRIPTOME
I - An overview of the transcriptome
The transcriptome ‒ the total collection of every RNA transcript in a cell ‒ provides a
unique readout of a cell’s commands as it executes its own genetic code. By extracting and
collating hundreds of thousands of these transcripts we can begin to assemble a detailed
snapshot of the cell’s activity at a particular point in time. This information can be sorted into large
expression patterns such that overarching trends emerge between cells, or it can be probed at a
single-transcript level to discern the activities of individual genes. Each single cell has a unique
transcriptomic “fingerprint” that is molded by the interior programming of its cell “type” as well as
exterior interactions with its surrounding microenvironment. Unlike traditional fingerprints,
however, the mammalian transcriptome is highly dynamic; the transcriptome fluctuates in
response to extracellular signals that promote cell division, metabolic functions, and other cellular
processes due to changes in transcriptional regulation at the genomic level.
Within a cell’s command center, the nucleus, RNA polymerases race down the DNA
double helix, unzipping its two strands and synthesizing an initial RNA copy (“pre-mRNA”) of a
gene at a rate of 50-100 nt per second (Singh and Padgett, 2009). Concurrently, an associated
enzyme caps the 5′ end of nascent pre-mRNA strands with a 7-methylguanosine moiety as
protection from nucleases and coordination to the ribosome. To further reinforce the pre-mRNA
strand against exonuclease degradation a poly(A) tail is appended to the message’s 3′ terminus.
These tails are typically 50-250 nt in length (Darnell et al., 1971), although some transcripts lack
tails altogether (Jalkanen et al., 2014). Completed poly(A) tails help to direct the transcript to
nuclear pores for transport out into the cytoplasm, where it can bind to ribosomes and related
machinery to engage in a steady state of protein expression. The amount of protein produced by
an individual transcript is tightly influenced by the length of its poly(A) tail: in general, shorter tails
often produce more transient bursts of transcription while longer tails are valuable for more even,
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long-term expression (Bresson and Conrad, 2013; Chen and Shyu, 2011). However, interactions
between the tail and neighboring sequence motifs as well as interactions between the tail region
and an assortment of other proteins can impart more nuanced effects on mRNA localization and
translation profiles (Zhang et al., 2010).
After polyadenylation, mature mRNA transcripts have an average length of ~2 kb.
Roughly 200,000 mRNA strands, decorated with translational machinery, drift through the cytosol
at a bulk concentration of 65-100 pM (Kempe et al., 2015). Individual mRNA species populate the
transcriptome at a wide range of abundances: nearly 50% of the pool is composed of <100
different mRNA sequences at 1,000-10,000 copies each. These are known as “high abundance”
mRNAs. Much of the remaining pool is split among a large number of so called “low abundance”
mRNA, roughly 10,000 different mRNA sequences with 10 or fewer copies each (Krebs et al.,
2013). As much as 90% of the total mRNA may be shared between various cell types
(“housekeeping genes”), with the remaining ~10% composed of highly diverse transcripts unique
to a cell’s function and environment. The work presented in this thesis focuses on protein-coding,
polyadenylated transcripts, but much of the transcriptome is composed of non-coding RNA which
regulate gene expression and perform a variety of other functions. For more information on the
rapidly evolving study of non-coding RNA, I direct the reader to a recent review by Deveson et al.
(Deveson et al., 2017).

II - The RNA-seq pipeline
Over the last decade, our understanding of the transcriptome has been revolutionized by
a major advancement in RNA sequencing (RNA-seq)(Wang et al., 2009). Compared to prior
hybridization-based microarray techniques, which were only capable of detecting already-known
transcripts, RNA-seq critically enabled de novo discovery of

formerly uncharacterized

transcripts. Its heightened signal-to-noise ratio lowered the sequencing background and helped to
detect RNA over a larger dynamic range of expression levels. RNA-seq also enabled more
complex analysis of RNA, including the ability to examine different isoforms and look at both
3

coding and non-coding RNA. Finally, over time it has managed to accomplish all of these
improvements while reducing costs and enabling higher throughput (Romero et al., 2018; Zhao et
al., 2014).
A variety of commercial single-cell RNA-seq platforms have emerged, including 10x
Genomics and Fluidigm C1, which combine preparative and sequencing steps into one process.
Currently, the most popular sequencing platform is Illumina’s “Sequencing-by-Synthesis” (SBS)
process. In this procedure RNA is initially isolated from cells and any contaminant genomic DNA
is digested away with DNase. Next, RNA is randomly broken up into 200-600 bp fragments by
shearing or other methods. These fragments can be linearly amplified with successive rounds of
cDNA generation and in vitro transcription, or they can be fitted with terminal adapter oligos that
function as primers for exponential PCR amplification, followed by cDNA generation. As a final
preparative step additional flanking sequences are ligated on, containing reference sequences
such as barcodes or other functional binding handles. The completed pool of amplified,
adapter-labeled cDNA sequences is referred to as a “library”. In Illumina’s dye-based
sequencing-by-synthesis method, adapter-capped library strands are loaded into an array of
millions of glass nanowells lining a flow cell. The base of each well is decorated by a “lawn” of
short well-bound oligo strands complementary to the 3′ adapters on incoming library strands.
Once the first library strand hybridizes to a well its complement strand is synthesized, setting off a
rapid bridge polymerase process (Ma et al., 2013) that copies the complement strand onto the
other roughly one thousand oligo stubs bound to the well, filling the well and excluding any other
library strands from binding. At this point the original library strands are denatured and washed
out, making room for new strands to be synthesized that match the sequences of the original
library strands. Instead of a rapid synthesis, however, the polymerases creating these new
strands are fed modified bases capped with base-specific, spectrally-distinct fluorophores which
terminate polymerization after addition. While polymerization is paused the entire cell is excited
and the fluorescent emission color of each well is used to identify its terminal base. After imaging,
the fluorophores are enzymatically cleaved from the terminal bases, allowing polymerase to add
4

the next base and repeat the cycle of imaging and fluorophore cleavage. More cycles produce
longer reads at higher costs. After the desired number of read cycles have been performed on the
forward strand, a reverse complement of the well-bound oligo is synthesized and the process is
essentially repeated in reverse.
During downstream analysis the forward and reverse reads are matched up in pairs, and
then overlapping read pairs are aligned to a reference genome. The number of observed reads
that align to a particular coordinate on the reference genome is typically referred to as “depth”,
with the sum of all depths across a given reference range referred to as the “coverage” (the exact
definition of these words is unfortunately variable between papers). Because competitive RNA
sampling methods detect higher abundance transcripts more commonly than lower abundance
transcripts, the top 1% most-highly expressed protein-coding genes can eat up ~40% of
sequencing reads (Deveson et al., 2017). Thus, studies aimed at lower abundance RNA may
need to perform more overall reads to have sufficient depth and coverage of these transcripts.

III - Single cell vs ensemble sequencing
The aforementioned advancements in whole transcriptome amplification as well as the
improved signal detection of modern RNA-seq methods have reduced the amount of requisite
starting RNA for transcriptomic studies from micrograms down to picograms, thus allowing for
single cell resolution (Gawad et al., 2016; Huang et al., 2015; Tang et al., 2009; Wang and Navin,
2015; Zong et al., 2012). Previously, it was necessary to homogenize bulk samples of seemingly
similar cell types to achieve an aggregate transcriptome. At best, these measurements might
successfully highlight some overarching shared features. However, hidden within that population
of seemingly identical cells there may be small subpopulations of cells with discrete and important
functions that are lost in averaging (Buettner et al., 2015). Worse still, it is possible that the entire
ensemble is more heterogeneous than expected, and the average transcriptome would not
accurately reflect any of the individual cells. In the simplest example, if half of the cell pool did not
express a particular gene and the other half of the pool expressed it highly, the aggregate
5

sequencing would report that all cells exhibited some median expression value. In a recent paper,
Hueck and colleagues outlined a number of potential scenarios where single cell heterogeneity
might be critical for achieving aggregate function within a tissue (Dueck et al., 2015). In particular,
maintaining cellular diversity helps a tissue to achieve faster or more dynamic responses to
environmental stresses (Briney and Crowe, 2013; Jaeger et al., 2013; Woods, 2014), and allows
a tissue to produce nuanced, graded effects, such as a gradient response to ligands and the
storage of complex information within the brain (Overton et al., 2014; Spencer et al., 2009). A
new frontier of biology involves building an understanding of complex, poorly understood tissues
‒ and even tissues that were previously thought to be well understood ‒ from the single cell level
up.

IV - Dissociative transcriptomic methods
In order to assemble a transcriptomic readout, mRNA must first be isolated from
individual cells. The last several years have seen an explosion of different isolation and
processing methods. The most popular of these methods ‒ CEL-seq2 (Hashimshony et al.,
2016), Drop-seq (Macosko et al., 2015), inDrop (Klein et al., 2015), MARS-seq (Jaitin et al.,
2014), and SCRB-seq (Soumillon et al., 2014) ‒ have all focused on the parallel processing of up
to a million cells from dissociated tissue. In these experiments a complex tissue of interest is
rendered down into single cells via enzymatic digestion. From there, the separated cells are
routed, single-file, through microfluidic channels into isolated reaction vessels such as microarray
wells or emulsion droplets. Within these reaction vessels the cells are lysed and primers are
added which feature unique molecular identifiers (UMIs) and poly(U) stretches to hybridize to the
poly(A) tails of the freshly liberated mRNA. Each UMI consists of a strand-specific code as well as
a cell-specific code shared by all strands in the same reaction vessel. The mRNA transcripts are
then converted to cDNA via reverse transcriptase, during which the UMI sequences are
incorporated into the newly minted cDNA strands. Because each cDNA is marked with its cell of
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origin, all of the cDNA can be pooled together, amplified, and then sequenced en masse. After
sequencing, the individual reads can be assigned back to their parent cell of origin, and
duplication artifacts introduced during amplification can be screened out thanks to the
strand-specific portion of the UMI code. Finally, having each strand tagged with a UMI gives the
expression scale an absolute minimum value instead of relying on relative values like reads per
kilobase per million reads (RPKM) (Islam et al., 2014). The transcriptomes of all of the cells can
then be clustered by their gene expression patterns via Principal Component Analysis (PCA) into
putative cell types. In this way potentially novel cell types are identified a priori.
In a recent example, Chen and colleagues sought to better understand previously
unexplored regions of the hypothalamus by examining the cell-type-specific effect of food
deprivation on the transcriptomes of hypothalamus cells within adult mice (Chen et al., 2017).
They sequenced 14,000 hypothalamus cells from mice that were food-deprived or fed ad libitum
and clustered the resulting transcriptomes into 11 non-neuronal and 34 neuronal cell types. They
further divided those clusters into putative cell-types and identified the specific neuronal clusters
that responded to food deprivation. Additionally, they identified novel neuropeptides involved in
the cluster’s signaling processes, and picked out an unambiguous combination of cell-surface
markers to facilitate additional studies. Eventually, targeted transcriptional surveys may link
together with overarching programs like the Human Cell Atlas initiative, the NIH Brain Research
through Advancing Innovative Neurotechnologies (BRAIN) Initiative, the European Human Brain
Project, and others which aim to generate a complete catalogue of every major cell type found in
the brain and other tissues (Regev et al., 2017; Rozenblatt-Rosen et al., 2017). Such catalogues
would serve as scaffolds upon which additional datasets could be interconnected, linking together
gene expression profiles with cell surface markers, morphological images, phenotype
descriptions, and more.
Massively parallel transcriptomic studies can not only further our understand of basic
human biology, but they can also be applied to disease systems. Darmanis and colleagues
utilized single cell transcriptomics to study glioblastomas, one of deadliest forms of brain cancer
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in adults owing to its highly invasive nature (Darmanis et al., 2017). Their results showed
substantial heterogeneity not only between tumors in different patients, but between cells within
the same tumor, suggesting that T-cell mediated immunotherapies targeting these glioblastomas
would require significant patient-specific tuning. However, migrating neoplastic glioblastomas
were shown to share some common transcriptomic signatures involving cell adhesion,
metabolism, apoptotic inhibition, and size regulation, which may elucidate future therapeutic
targets. Single cell transcriptomics has also been used both to better understand and
subsequently predict drug sensitivity (Chang et al., 2003; Costello et al., 2014; Lamb et al., 2006;
Staunton et al., 2001). While the potential therapeutic rewards may seem distant, single cell
transcriptomics is already driving actionable findings in the clinic. Incorporation of tumor
sequencing data into a 2015 trial for the management of relapsed cancer in youths allowed
clinicians to make predictions on the pathogenicity of recurring tumors by comparing them to
databases of tumor sequences (Mody et al., 2015). For one patient, standard treatment options
failed, but sequencing results predicted good sensitivity to a tyrosine kinase inhibitor, imatinib.
The patient went in remission with excellent quality of life while taking imatinib for the following 21
months. A similar study was conducted at Columbia University Medical Center which discovered
likely pathogenic germline alterations in 20% of patients, aided diagnostic information in 26% of
patients, and identified therapeutic targets in 23% of patients. The sequencing was overall
determined to have been clinically impactful in 66% of cases (Oberg et al., 2016). In a final
clinical trial, a wide variety of metastatic tumors were sampled and sequenced, which helped to
sort the tumors and guide future treatments based upon potential drug responses (Robinson et
al., 2017).

V - Spatial transcriptomic methods
Dissociative transcriptomic methods create huge data sets with significant discovery
power and therapeutic predictive potential. However, what these methods gain in scale and
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statistical power they lose in contextual quality: dissociated cells lack any spatial information, and
without knowledge of a cell’s point of origin within an organ or its surrounding microenvironment,
interpreting the significance of the cell’s heterogeneous expression becomes more challenging.
Therefore, another field of single cell transcriptomics has focused on elucidating spatial features
of the transcriptome utilizing fluorescent in situ hybridization (FISH) (Langer-Safer et al., 1982).
FISH methods employ fluorescent oligonucleotide (oligo) probes complementary to specific
known transcript sequences to visually pinpoint and quantify those transcripts in fixed,
permeabilized tissue under fluorescence microscopy. The number of different sequences that can
be detected is limited by spectral crowding of its fluorophores, and the detection of individual,
low-abundance transcripts is limited by diffraction and fluorescence intensity. To circumvent
spectral crowding current FISH evolutions employ a unique combination of fluorophores for each
transcript, multiplexed either spatially ‒ with multiple unique fluorophores per probe ‒ or
temporally ‒ with secondary fluorophores that are bound and stripped in successive imaging
passes (Levesque et al., 2013; Lubeck et al., 2014). Multiplexing expands the number of different
sequences that can be imaged in a single experiment to over one hundred. To further boost the
fluorescence signal above cellular background fluorescence, amplification techniques such as
single-molecule hybridization chain reaction (smHCR) or tissue clearing procedures can be
incorporated (Shah et al., 2016). Adaptations such as superresolution microscopy (Perkel, 2016)
and expansion microscopy enable these methods to break the diffraction limit and image single
molecules (Cho et al., 2018). Finally, to reduce the incidence of false-positives (especially
prevalent in temporal multixing applications with potential tissue movement between imaging
rounds) the Zhuang lab incorporated a modified Hamming code into its probes as a form of
error-correction (Wang et al., 2018).
Spatial transcriptomic methods are poised to make important contributions in the
understanding of complex tissue organization, which is especially crucial during development, in
understanding neuronal connectivity, and in various disease states (Lein et al., 2017). Grasping
the intricacies of development requires careful spatial tracking of morphogenesis, migration,
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differentiation, and patterning events. Spatial information about these developmental processes
becomes even more powerful when a psuedo-time component is added by either inferring or
directly recording cell lineage information. One method, MEMOIR (memory by engineered
mutagenesis with optical in situ readout) (Frieda et al., 2017) utilizes CRISPR/Cas9-directed
mutagenesis of RNA scratchpads to record an inheritable ID code that can be read by smFISH.
Study of neuronal connectivity with traditional methods like patch clamp electrophysiology is
complimented by downstream transcriptomic analysis. Approaches like Barcoding of Individual
Neuronal Connections (BOINC) (Zador et al., 2012) and its imaging-based variant (FISSEQ
BOINC) (Marblestone and Boyden, 2014) further aid in elucidating the connectome by creating
random barcodes in cells that become merged at synapses. Finally, many diseases are
associated with a disrupted organization within a tissue. Keren-Schaul and colleagues recently
utilized single-cell RNA-seq to identify an activated microglia near Alzheimer’s plaques as a
potential therapeutic target (Keren-Shaul et al., 2017), and understanding the development and
complex organization of tumors is a promising strategy towards developing further treatment
options.
FISH methods have also become common tools in many microbiological diagnostic
laboratories, where they can be used to detect sequences specific to individual species of
Gram-positive cocci, Gram-negative cocci, and yeast in clinical samples. The approach is
attractive primarily due to its relatively fast turnaround time (60-90 min), ability to directly analyze
primary clinical material without additional culturing, and relatively low cost of instrumentation
compared to competing MALDI-TOF-MS methods (Frickmann et al., 2017). In addition to
detecting invasive microbiological species, FISH has also been used to assist traditional
histopathological diagnosis of cancers such as melanoma (Ferrara and De Vanna, 2016).
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VI - A niche between popular methods
As previously alluded, popular transcriptomic methods present clear strengths coupled to
significant drawbacks. The process of dissociating tissue can impart significant perturbation and
technical variation upon processed cells. After a tissue is dissected from an organism it
undergoes mechanical mincing to break it into smaller pieces. From there the extracellular matrix
is digested with a protease cocktail under additional mechanical agitation. The released single
cells may then be processed by flow cytometry or centrifugation to enrich cell types of interest
(Nguyen et al., 2018). Finally, these cells are routed through microfluidic devices to their
sequencing chambers. The combination of mechanical and chemical stresses in addition to the
relatively lengthy time between processing and sequencing can make it challenging to separate
out technical perturbation from functionally important heterogeneity and reconstruct an image of
the transcriptome that is authentic to the beginning of the experiment (Alles et al., 2017).
Furthermore, sequencing a vast number of cells can be at odds with sequencing cells at a
sufficient depth to study low abundance transcripts. Finally, dissociative methods lose the context
of spatial information. Conversely, spatial methods such as FISH-variants preserve spatial
information, successfully image low-abundance transcripts, and capture a finer temporal window
of the transcriptome due to fast fixation times. However, such methods can only process a limited
number of known genes in a single experiment. Furthermore these methods require tissue
sections to be fixed with methanol or formaldehyde. While fixation offers spatial methods
improved temporal control relative to dissociative methods, and lineage reconstruction with
scratchpads and other elements offer a pseudo-time element, neither method allows for capture
of mRNA at multiple time points in a tissue region, or the continued observation of a tissue region
after the point of mRNA capture.
Due to these shortcomings, our lab previously sought to design a new photochemical
approach to single cell transcriptomics. Drawing upon the rich history of caged oligonucleotides
we engineered an oligo probe capable of attaching biotin noncovalently to mRNA in target cells
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within living tissue upon photoactivation, allowing for subsequent pulldown. Fluorophores enable
tracking of probe-labeled cells during development or migration events, and isolated mRNA from
target cells can be sequenced to allow for complete profiling of the transcriptome, rather than
specific known genes. The specifics of this method, Transcriptome In Vivo Analysis (TIVA), will be
discussed further in Chapter 2. In the remaining half of this introduction ‒ a partial adaptation of
our 2015 review (Ruble et al., 2015) ‒ we will examine the history of caged oligonucleotide
probes and discuss current oligo technologies that have informed the design of the TIVA probe.

INTRODUCTION PART 2: CAGED OLIGONUCLEOTIDE PROBES
I - Light as a chemical trigger
Photochemical reactions frame our daily lives. Each morning as the sun rises it casts
blue light upon photoreceptors in our retinas. There, excitation of the photopigment melanopsin
propagates a signal to the suprachiasmatic nucleus in our hypothalamus, effectively
synchronizing our internal master clock with the exterior world (Fisk et al., 2018; Tosini et al.,
2016). Throughout the day photosynthesis by plants and other organisms provides oxygen for us
to breath, and carbon stored as a result of photosynthesis forms the energetic foundation of the
food we consume at each meal (Jensen and Bassham, 1966). At the end of the day an absence
of blue light gradually tempers our alertness until the onset of sleep (Kessel et al., 2011).
As our eyes demonstrate, light can penetrate rapidly and noninvasively into our tissues.
In the rest of our body, where light is orthogonal to most biological processes, light can be
delivered to specific sites at calculated doses with high spatial and temporal resolution. The ability
to deliver light quickly, with fine control, and without risk of disrupting endogenous processes has
led to the adoption of light as a trigger in the study of biological systems. In 1978 J.F. Hoffman
described a methodology for holding molecules inactive until they could be returned to an active
form with light (Forbush et al., 1978). He referred to this process as “caging”, and while the term
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“caging” may conjure images of something trapped within iron bars, perhaps a better analogy
would be a car that’s prevented from driving by a single clamp (or “boot”) on one of its wheels.
That is, instead of trapping molecules in a superstructure, we identify a key functional site to
cover with a covalently-attached, photoremovable protecting group. Blocking of this key site limits
the molecule’s binding or activity until a photochemical reaction initiated by near-UV, visible, or
near-IR light can remove the protecting group and allow the molecule to assume an active form
(Adesnik et al., 2005; Chambers et al., 2004; Ellis-Davies, 2007; Gardner et al., 2011; Lima and
Miesenböck, 2005). A wide variety of compounds have been photocaged. Early works focused on
caging smaller molecules, such as cationic calcium (Adams et al., 1988; Ellis-Davies and Kaplan,
1994; Kaplan and Ellis-Davies, 1988), neurotransmitters (Matsuzaki et al., 2001; Milburn et al.,
1989; Walker et al., 1986; Wieboldt et al., 1994), nucleotides (Kaplan et al., 1978; Walker et al.,
1988), and peptides (Rothman et al., 2005; Walker et al., 1998) since a single photocage could
impart a large functional perturbation to these compounds.

II - Organic caging groups
An ideal caging group must (1) be easily installed, (2) remain stable prior to
photo-activation, (3) have a high quantum yield and fast reaction kinetics for removal with the
briefest amount of irradiation, and (4) remain inert to the rest of the system after activation. One
of the most common caging groups is the ortho-nitrobenzyl group, which can be readily appended
to a nitrogen, sulfur, or oxygen. Nitrobenyzl derivatives are typically activated with UV or near-UV
light. The nitrobenzyl core has been widely tweaked in the last several decades, with additions to
the benzylic carbon as well as additions to the aromatic ring, such as methoxy or methylenedioxy
groups to raise quantum yield, carboxylic acids to improve solubility, or additional substituent
chains to make the group function as a cleavable linker (Klán et al., 2013). Quantum yields and
reaction kinetics vary, but the nitrobenzyl phosphoramidite introduced by Ordoukhanian and
Taylor (Ordoukhanian and Taylor, 1995) that will be the focus of this thesis has a relatively high
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quantum yield (0.49-0.63) and exhibits ~80% photorelease of its substrate within seconds
(Hausch and Jäschke, 2001; Horspool and Lenci, 2003). Release of the o-nitrobenzyl group
begins with excited state intramolecular hydrogen transfer from the benzylic proton to the nitro
group, which subsequently attacks the oxidized benzylic carbon to create a heterocycle.
Deprotonation of the hydroxylamine causes the heterocycle to collapse, liberating the substituent
previously attached to the benzylic carbon (Kim and Diamond, 2006).
Coumarin derivatives are another popular class of organic photocaging groups. Initially
used to cage diethyl phosphate (Givens and Matuszewski, 1984), coumarin derivatives were
found to be compatible with a wide range of nucleophiles, undergoing solvent-assisted
photoheterolysis upon activation. Relative to nitrobenzyl groups, coumarin derivatives generally
offer larger extinction coefficients farther into the visible range, larger 2-photon cross-sections,
higher photolysis efficiencies, and faster release kinetics (Falvey, 2005). Coumarins have been
similarly tuned with modifications to the coumarin ring to tweak absorption and solubility
properties.

Currently,

the

most

widely

used

coumarin

derivative

is

DEACM

(7-(Diethylamino)-4-(hydroxymethyl)coumarin) (Menge and Heckel, 2011), but more cutting-edge
advancements include the addition of dicyano groups to the coumarin cage (DEAdcCM) which
push 1-photon absorption into the green (Gandioso et al., 2017) as well as the attachment of
coumarin to additional 2-photon sensitizers (Hammer et al., 2018), which extend 2-photon
absorption into the near-IR 740-900 nm range. The combination of multiple caging groups that
can be sequentially activated with distinct wavelengths of light enables multiplexed applications
(Yamazoe et al., 2014).
Covering all photocaging compounds ‒ including phenacyl groups (An et al., 2010;
Banerjee and Falvey, 1998; Wang, 2013), benzyl-based groups (Birr et al., 1972; Chamberlin,
1966), and others ‒ as well as the many derivatives of the aforementioned compounds is not
possible within the scope of this introduction. For a deeper discussion of reaction mechanisms
and applications I direct the reader to a review by Klán and colleagues (Klán et al., 2013), and for
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more historical perspective I direct the reader to a text edited by Goeldner and Givens (Falvey,
2005).

III - Design of caged oligonucleotides
Oligonucleotides are attractive caging targets due to their potential to manipulate DNA,
RNA, or protein function. However, the larger size of these potential caging targets relative to
simpler signaling molecules has necessitated more complex caging strategies. Plasmids, in
particular, were especially challenging to cage because they were too large to synthesize de
novo. Instead, Monroe and colleagues attempted to cage a plasmid by installing roughly 270
DMNPE ( 1-(4,5-dimethoxy-2-nitrophenyl)diazoethane) groups along its phosphate backbone
(Monroe et al., 1999) (Figure 1A). This strategy resulted in only partial plasmid activity after
photolysis.

Ando

and

colleagues

later

utilized

more

photosensitive

6-bromo-4-diazomethyl-7-hydroxycoumarin moieties at every ~35 bases to cage GFP plasmid or
mRNA, and successfully achieved activity after uncaging them with near-UV light (Ando et al.,
2001, 2005). An innovation by Hemphill and colleagues abandoned statistical caging of the entire
backbone in favor of more targeted caging of the plasmid’s promoter region: with up to three
NPOM-caged (6-nitropiperonyloxymethyl) thymidines in a GFP plasmid’s promoter they were able
to block expression of GFP in zebrafish embryos until 356-nm activation (Hemphill et al., 2014).
Short oligos could be more effectively caged by random backbone caging groups (Figure 1B).
Development of a caged thymidine phosphoramidite (Kröck and Heckel, 2004; Young et al., 2008)
facilitated the design of site-specific caging strategies in synthesized oligos (Figure 1C). SiRNA
knockdown strategies could implement terminal protecting groups to block RISC binding with a
small number of caging moieties (Figure 1D) (Nguyen et al. 2006; Shah et al. 2005; Blidner et al.
2008), or they can incorporate caged bases directly into the antisense strand of the siRNA duplex
(Figure 1E) (Mikat and Heckel, 2007).
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In addition to sterically blocking activity of key sites, another approach is to use a
photocleavable linker (PCL) to create a light-responsive, site-specific strand-break within the
oligo. With careful placement, such strand-breaks can potentially generate large changes in the
oligo’s secondary structure and subsequent activity. The first widely adopted method of
introducing a photocleavable linker into an oligo was the development of a nitrobenzyl-linker
phosphoramidite by Ordoukhanian and Taylor, which could be incorporated during solid-phase
synthesis (Ordoukhanian and Taylor, 1995). Our lab has utilized photocleavable linkers to drive a
number of different oligo functionalities. One of the first approaches to turning gene expression
“ON” with light was to create an RNA bandage, consisting of two antisense strands joined by a
nitrobenzyl-based PCL. Prior to photolysis the bandage would bind to a target start codon and
Kozak sequence in the 5′-UTR to block translation of an mRNA (Figure 2A). After photolysis, the
two short strands of the bandage would exhibit a decreased melting temperature with the mRNA,
dissociating away and restoring translation. This approach was effective, but required tedious
sequence-specific tuning of the bandage strand lengths to achieve a suitably high Tm prior to
photolysis and low Tm after photolysis (Richards et al., 2008). To turn gene expression “OFF” with
light our lab again utilized a hairpin approach where an 18-to-25mer antisense oligo was tethered
to its complement sequence by a PCL. The two strands hybridized, creating a hairpin motif that
blocked binding of the antisense strand to its target. After photolysis the melting temperature was
once again decreased, freeing the antisense strand to bind to its target mRNA (Figure 2B)
(Griepenburg et al., 2013; Richards et al., 2010; Ruble et al., 2012). The Chen lab has applied
this design scheme to the study of how ntla regulates notochord development in zebrafish
(Ouyang et al., 2009; Shestopalov et al., 2007, 2012), leveraging the method’s spatiotemporal
control to study the various roles ntla performs in different embryonic areas over progressive
developmental stages. The hairpin design can also be applied to the study of microRNA (miRNA).
First developed by the Li lab (Li and Zheng, 2012), hairpin-caged antagomirs bind to miRNA after
photolysis, blocking their activity. To connect the antagomir to its blocking strand they utilized a
bifunctional coumarin linker. This design could be successfully photoactivated to selectively block
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lys-6 miRNA activity in C. elegans, but the hairpin still exhibited some background activity prior to
photoactivation. To improve caging while still allowing for effective photoactivation we utilized a
longer blocking strand with two photocleavable nitrobenzyl linkers in our antagomir design (Figure
2C) (Griepenburg et al., 2013). The resulting construct could block let-7 miRNA activity in
zebrafish embryos with minimal background pre-photolysis.
A potentially more elegant approach to caging involves bending a linear strand into a
circular (or “cyclic”) conformation to cage it sterically rather than relying upon a complementary
blocking strand. While early implementations inspired by circular DNAzymes still utilized blocking
strands and functioned more like circular hairpins (Figure 2D) (Richards et al., 2010; Seifert et al.,
2006), Tang and colleagues introduced circular antisense oligos without blocking strands,
circularized by a 1-(2-nitrophenyl)-1,2-ethanediol (NPE) linker (Tang et al., 2010; Wu et al., 2013)
(Figure 2E). In their experiments, photoactivation of the NPE linker linearized the antisense
strand, enabling RNase H-mediated degradation of a target RNA. To examine the role of circle
strand length in steric caging, they synthesized oligos with sizes ranging from 20mers to 40mers.
Generally, the larger loops successfully enhanced target RNA degradation upon photolysis, but
still exhibited an unacceptable amount of background degradation prior to activation. Shorter
loops showed minimal background degradation ‒ presumably due to their greater conformational
restriction ‒ and a >20-fold enhancement of target degradation once activated. The Chen lab
adopted this circular design and applied it in vivo with a morpholino construct targeting the ntla
gene in zebrafish embryos (Yamazoe et al., 2012). Their 21-to-25mer morpholinos (cMO) were
circularized by a bifunctional 4,5-dimethoxy-2-nitrobenzyl (DMNB) linker attached to the oligos
with thiol-maleimide chemistry. Cyclic morpholinos were injected into zebrafish zygotes and
irradiated in +light samples at 3 h post-fertilization. At 24 h post-fertilization the resulting ntla
phenotypes were scored: 90% of the photoactivated embryos demonstrated a complete ntla
phenotype, although 25% of the unactivated embryos exhibited varying degrees of the ntla
phenotype as well. While these results highlight potential background issues with circular oligos,
they performed as well or slightly better than similar hairpin designs, with the benefit of easier
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synthesis and less purification. In a follow-up collaboration between the Deiters and Chen labs,
they demonstrated that multiple cyclic morpholinos with different photocleavable linkers could be
sequentially activated in zebrafish embryos (Yamazoe et al., 2014): a DEACM-linked MO
targeting flh could be activated with 405 or 470 nm light, while a NB-linked MO targeting spt could
be later activated by 365 nm light. This proof-of-concept experiment demonstrated the potential
for multiplexed knockdown in vivo studies. However, because DEACM and NB share some
spectral overlap in absorption, the initial activation of DEACM at 470 nm still resulted in minor
activation of NB. This highlights the need for caging groups that can be activated at longer
wavelengths to achieve more spectrally-distinct activation windows. Inorganic ruthenium
complexes offer many potential improvements to 2-photon, visible light activation, and will be
discussed further in Chapter 5.

IV - Oligonucleotide backbone modifications
To improve the performance of oligo probes during in vivo experiments, a large variety of
functional modifications have been developed, aiming to improve nuclease resistance, raise
target-binding affinities, stabilize certain structural conformations, reduce immunogenicity, and
more. Such modifications can be categorized by their location in the oligo backbone, sugar, or
nucleobase.
Backbone modifications tweak the internucleotide phosphodiester group or even replace
it completely, often with the goal of reinforcing the backbone against degradation by endo- and
exonucleases. One of the first modifications replaced one of the phosphodiester’s non-bridging
oxygens with sulfur to create a phosphorothioate (PS) linkage. Each PS linkage adds a point of
chirality to the backbone, and both stereoisomers can have unique properties ‒ for example,
certain phosphodiesterases will only cleave the Sp isomer, while others cleave the Rp isomer,
based upon how the isomer geometry and the altered metal-coordination of the sulfur relative to
oxygen affect binding of the backbone to phosphodiesterase active sites (Brautigam and Steitz,

18

1998; Steitz and Steitz, 1993; Zhang et al., 1999). In addition to nuclease resistance, PS
compounds can also mediate uptake into certain cell types without the need for an additional
delivery vehicle (Stein et al., 2009). This may be attributed to the adsorption of non-specific
proteins onto the surface of the phosphorothioated oligo, shuttling it through an endocytic path
into the cell. The benefits of nuclease resistance and improved uptake come at a cost, however.
Each PS linkage decreases the binding affinity of the parent strand to its complement. For this
reason, PS linkages are typically introduced at specific terminal sites unless additional protection
against endonucleases is required. Additionally, PS linkages may increase toxicity. Despite these
risks, phosphorothioated antisense oligos were widely used for early therapeutic antisense oligos
(Bennett and Swayze, 2010; Sanghvi, 2011).
In morpholino oligos a methylenemorpholine ring replaces the sugar and a
phosphorodiamidate linkage replaces the phosphodiester linkage. The neutral charge and altered
geometry of the modified backbone and sugar grant morpholinos high resistance to nucleases as
well as increased target-binding affinities. Although they’re incompatible with RNase H-dependent
degradation pathways they can still bind directly to mRNA or miRNA to interfere with their
function. These attributes led to the adoption of morpholinos as the antisense oligo of choice for
developmental studies in model organisms including zebrafish, frogs, sea urchins, chickens, and
more over the last several decades (Blum et al., 2015). However, more recently, concerns have
been raised over non-specific effects caused by morpholino oligos, with many of the more severe
phenotypes in morpholino-treated organisms arising from the morpholino itself (Kok et al., 2015).
These concerns, combined with restrictive distribution rights, may lead to decreased usage of
morpholinos in the future.
Peptide nucleic acids (PNA) similarly utilize neutrally charged backbones for improved
nuclease resistance and tighter binding at the cost of RNase H compatibility (Kok et al., 2015;
Nielsen et al., 1994a). Rather than a traditional sugar and backbone, PNAs consist of repeating
N-(2-aminoethyl)-glycine units connected by peptide bonds, with sugars attached by methylene
carbonyl linkers. Traditional uncharged PNAs exhibit decreased solubility and cell permeability as
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well as increased rates of aggregation. These issues can be mitigated with a number of different
backbone alterations that can introduce additional positive or negative charges or other features,
one of the most successful being (R)-diethylene glycol units (Sahu et al., 2011). One curiosity to
note is PNA’s tendency to insert itself into double-stranded DNA, either by traditional
Watson-Crick or Hoogsteen base-pairing (Uhlmann et al., 1998). This behavior has been
harnessed to create gene-disrupting therapies (Hanvey et al., 1992; Nielsen et al., 1994b), and
the high stability of PNA has been utilized for more traditional antisense, PCR, and FISH
applications (Quijano et al., 2017).

V - Oligonucleotide sugar and nucleoside modifications
Modifications to the oligonucleotide sugar alter its puckering preferences to affect the
oligo binding characteristics. 2′-OMe nucleosides adopt a “North” (C3′ endo) sugar conformation,
which promotes an A-form RNA helix prior to hybridizing (Kawai et al., 1992; Nishizaki et al.,
1997). A 2′-OMe RNA strand hybridized to RNA has a 1.3 °C higher Tm per modified base relative
to a DNA:RNA duplex of the same sequence (Kawasaki et al., 1993), and 2′-OMe
phosphoramidites have higher coupling rates and more convenient synthesis than traditional
RNA. Furthermore, 2′-OMe RNA is well suited for application in siRNAs, where it has been shown
to have lower immunostimulatory effects (Whitehead et al., 2011), while increasing nuclease
stability (Rettig and Behlke, 2012). Another popular 2′ modification is the addition of a fluoro
group. Similarly to 2′-OMe, 2′-F pushes the ribose sugar into a North conformation to promote
A-form helix formation (Ikeda et al., 1998), but fluorine electronegativity also drives base stacking
(Pallan et al., 2010). The resulting combination offers a 2-3 °C increase in Tm per fluoro modified
base for 2′-F RNA:RNA duplexes relative to DNA:RNA duplexes. Unlike 2′-OMe RNA, 2′-F hasn’t
been found to significantly increase exonuclease resistance but does offer some protection
against endonucleases that target pyrimidine-rich strands (Manoharan, 1999). The epimer of 2′-F
ribose, 2′-deoxy-2′-fluoro-β-D-arabinose (2′-F-ANA), adopts a South/East pucker to more closely
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resemble DNA. It offers better nuclease resistance and has demonstrated improved cellular
uptake and activity in antisense applications (Deleavey et al., 2010; Dowler et al., 2006), but has
a Tm stabilization closer to 2′-OMe RNA (Damha et al., 1998). Another approach to manipulating
sugar conformations is to rigidify the structure with additional linkages. Locked nucleic acid (LNA)
joins the 2′-OH and C4′ with a methylene bridge. Covalently fixing the ribose into a North pucker
offers the highest Tm stabilization of any of the sugar modifications discussed so far, at roughly
5.6°C per modified base (Koshkin et al., 1998). LNAs also reduce nuclease degradation and
immunostimulation (Whitehead et al., 2011). Together, these advantages have lead to widespread
use of LNA in both antisense (Braasch and Corey, 2001) and siRNA applications (Blidner et al.,
2008; Braasch et al., 2003; Elmén et al., 2005; Hornung et al., 2005).
Nucleobase modifications typically aim to maintain or improve base pairing specificities
while enhancing oligo activity or offering unique functionalities such as fluorescence for imaging
(Dodd and Hudson, 2009). For example, additions of iodo or bromo groups to the 5 position of
uracil improve binding to adenines (Watts et al., 2008). The Burrows lab demonstrated a
reduction in immunostimulatory effects by appending alkyl groups to the N2 position of guanines
(Peacock et al., 2011a). These alkyl groups were thought to reduce binding to cytokines, but they
must be added to key positions to have a beneficial effect. For further information on nucleobase
modifications I direct the reader to a thorough review by Peacock and colleagues (Peacock et al.,
2011b), and for general information on oligonucleotide modifications I recommend Deleavey and
Damha’s 2012 review (Deleavey and Damha, 2012).

VI - Delivery strategies
Achieving effective delivery of oligonucleotide probes to the cellular cytosol has been an
ongoing challenge since the 1980s, as the majority of oligos remain trapped in maturing
endosomes. To date, most strategies have fallen into two principal categories: encapsulating the
oligo within some sort of ionically-associated nanocarrier, or directly modifying the oligo with a
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covalently-attached ligand or other moiety than can trigger cell uptake. Nanocarriers are attractive
because they do not complicate oligo synthesis and can potentially protect oligos from
degradation during delivery (Wang et al., 2015). The most popular nanocarriers are lipid
nanoparticles (LNP) such as lipofectamine, which are often cationically charged to condense
oligo payloads and mediate interaction with cellular membranes. After triggering endocytosis,
cationic lipids disrupt endosomal membranes by forming an inverted hexagonal phase that allows
leakage of the endosomal contents (Marrink and Mark, 2004). Lipid nanoparticles offer relatively
reliable delivery into cultured cells, but interactions with opsonic proteins in the blood can impede
delivery in whole organisms unless the cationic lipids are coated with a neutral polymer such as
polyethylene glycol (Mui et al., 2013). Recent efforts have focused on adding targeting functions
to LNPs with antibodies (Ramishetti et al., 2015; Sriraman and Torchilin, 2014) or aptamers
(Wilner and Levy, 2016), and improving delivery to areas outside of the liver. Another class of
nanocarriers are polymeric nanoparticles such as polyethylene imine (PEI) (Babu et al., 2014;
Patil et al., 2010). Like lipid nanoparticles, PEI condenses associated oligos, and the resulting
polyplex can trigger endocytotic uptake. However, unlike LNPs, PEI complexes mediate
endosomal escape via osmotic swelling and subsequent endosomal lysis (Akinc et al., 2005;
Rudolph et al., 2000). Other polymeric carriers include tri-block polymers (Biswas et al., 2013)
and hydrogels (Dong et al., 2011; Moreno et al., 2018). Both lipid and polymeric nanoparticles
come with the potential for cell toxicity, however, as their cationic character leads them to bind to
anionic

macromolecules

and

disrupt

cell

membranes

at

higher

concentrations.

Ionically-associated cell penetrating peptides (CPPs) offer uptake with potentially lower toxicity.
One such CPP, PepFect6 (PF6), combines a stearylated TP10 peptide for initial uptake with a
trifluoromethylquinoline group for endosomal escape (Andaloussi et al., 2011). The Langel lab
demonstrated that PF6-complexed siRNAs were capable of mediating gene knockdown in a
variety of organs in mice following systemic delivery.
More recently, research has turned to focus on conjugating oligos with individual delivery
moieties. Although potentially more labor-intensive, this controlled approach aims to make each
22

oligo more molecularly defined compared to a mass of nanoparticles, while also avoiding some of
the aforementioned toxicity and non-specific binding issues plaguing larger carriers. Some
delivery agents can be attached during solid-phase synthesis, alternatively, a terminal amine,
azide, or thiol can be incorporated to enable conjugation in solution after cleavage. Early
conjugates such as cholesterol (Soutschek et al., 2004) and other fatty acids preferentially
mediated uptake into the liver by lipoprotein receptors, and suffered from low delivery efficiencies.
Peptide conjugates can target specific receptors, such as the cyclic Arg-Gly-Asp (RGD) peptide
to the VEGF receptor (Liu et al., 2014), or they can offer more generalized uptake with carriers
such as (Arg)9, Antennapedia, or TAT. The exact mechanisms for delivery by these peptides vary
depending upon their charge and hydrophobicity (Dinca et al., 2016; Eiríksdóttir et al., 2010).
Finally, oligos can also be tethered to serum proteins such as albumin (Kang et al., 2008;
Kuhlmann et al., 2017), which can disguise the oligo against nucleases and reduce its
immunogenic profile, potentially extending its viable circulation time by hours or days. For further
reading on current oligo delivery strategies I direct the reader to a recent review by Rudolph
Juliano (Juliano, 2016).
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Figure 1.1 Various approaches for caging oligonucleotide function using photoresponsive blocking groups or
linkers (in orange). (A) Plasmid with phosphate backbone caged is unable to be expressed until photolysis
with near-UV light removes the caging groups. (B) Caging of the phosphate backbone of antisense
oligonucleotides prevents them from hybridizing to their mRNA target until the caging groups are removed
with light. (C) Antisense oligonucleotides with caged nucleobases incorporated during solid phase synthesis
are unable to bind their target. After irradiation with near-UV light, the caging moieties are removed, allowing
the antisense strand to bind its target. (D) siRNA molecules caged at the 5′-end of the antisense strand are
inactive until after near-UV exposure.
Adapted from Ruble et al. J. Inorg. Biochem. 2015 Sep; 150: 182–188.
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Figure 1.2 Caged oligonucleotide strategies utilizing photocleavable linkers. (A) RNA bandages consist of
two tandem oligonucleotides (green and blue) linked by a photocleavable linker (orange). Prior to irradiation,
the bandage binds the mRNA target to prevent translation. After photolysis, the short oligonucleotide strands
dissociate from the mRNA, allowing translation to occur. (B) DNA hairpins are comprised of an antisense
oligonucleotide (red) linked via a photocleavable linker to a blocking strand (green). Upon near-UV
irradiation, the antisense strand is able to bind to its mRNA target (gray) and inhibit translation. (C)
Antagomirs are structurally similar to hairpins, but the blocking strand (green and blue) is divided into two
parts by a second photocleavable linker. This design allows the blocking strand to be as long as possible
before uncaging, efficiently blocking the antisense strand from binding to its target microRNA. (D)
DNAzymes and microRNA molecules can be caged by synthesizing oligonucleotides with photocleavable
linkers and then circularizing. Exposure to near-UV light results in release of the active, linear oligo. (F)
Circular caged oligonucleotides are inactive until the molecules are irradiated.
Adapted from Ruble et al. J. Inorg. Biochem. 2015 Sep; 150: 182–188.
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Chapter Two
Synthesis optimizations of first-generation Transcriptome In Vivo Analysis (TIVA)
probe and corresponding collaborations

Partially adapted from:
S.B. Yeldell et al. Org. Biomol. Chem. 2017, 15 (47), 10001–10009.
D. Lovatt et al. Nat. Methods 2014, 11, 190–196
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Motivation and design of first-generation TIVA
As we discussed in the Introduction, popular transcriptomic methods are poorly equipped
to capture the complete transcriptome of individual, living cells still contextualized within the
native microenvironment of their parent tissue. Typically, these experiments are performed by
extracting cells of interest by patch-pipette aspiration (Tang et al., 2009). The process of cleanly
extracting single cells out of complex tissue is mechanically challenging, however, and in more
entangled tissues such as the brain, isolating an intact single cell without capturing pieces of any
neighboring cells can be nearly impossible. Furthermore, the process of patch-pipette aspiration
adds additional perturbation to the captured transcriptome. For these reasons our lab sought to
create a capture protocol that could use light to selectively isolate mRNA from a
software-delineated region encompassing a single cell, surpassing the dexterity limits of manual
patch-pipette aspiration.
To accomplish this, our lab built on its experience in the design, synthesis, and
characterization of hairpin oligonucleotide probes. Most recently our lab had determined that
hairpins with longer blocking strands and two photocleavable linkers ‒ one PCL in the hairpin turn
and another in the middle of the blocking strand ‒ offered a high Tm and subsequently improved
caging pre-photolysis, while still achieving complete release of the active strand upon photolysis
(Griepenburg et al., 2013). Hairpin-caged antagomirs were previously shown to be capable of
binding to mRNA upon photolysis, so a natural evolution of this strategy was to change the oligo
probe binding site from a strand-specific sequence to a sequence shared by the majority of
mRNA ‒ the poly(A) tail. This results in a poly(U) “capture” strand caged by two poly(A) “blocking”
strands, with all three strands joined into a hairpin by two nitrobenzyl-based photocleavable
linkers. An 18mer capture sequence was estimated to be the shortest length necessary to
specifically bind to and pull down mRNA, and because the nitrobenzyl-based photocleavable
linker was equated to ~four bases in length, two 7mers were chosen to cover the 18mer capture
strand. To report upon the probe’s caging and activation state in cells a Cy3-Cy5 FRET reporter

37

pair was added to the ends of the hairpin. Lastly, to deliver the probe, a (D-Arg)9 cell-penetrating
peptide was appended to the 5′ terminus via disulfide linkage. To pull the probe-bound mRNA out
of the cells, a biotin moiety was appended to the 3′ terminus (Figure 2.1).
In a typical Transcriptome In Vivo Analysis (TIVA) experiment ‒ performed by our
collaborators, the Eberwine lab, at the Medical School of the University of Pennsylvania ‒ brain
tissue collected from sacrificed mice or from human patients undergoing brain surgery is rushed
from the operating room to a dark lab, where it’s sectioned into layers a few cells thick and
soaked in a PBS solution with ~6 µM TIVA probe. Over the next 30-90 minutes, (Arg)9 (possibly
assisted by transient permeabilization from sectioning) mediates uptake into the majority cells,
labeling them with a Cy5 FRET signal (upon Cy3 excitation at 543 nm) observable by laser
scanning confocal microscopy. Once sufficient TIVA probe has reached the cytoplasm, confocal
software is used to carefully trace a perimeter around the target cell, and a 405-nm laser rasters
over the target area for a few microseconds per pixel. Within the target cell, 405 nm light initiates
cleavage of the nitrobenzyl linkers and subsequent displacement of the short poly(A) blocking
strands by the longer stretches of mRNA poly(A) tails. As the blocking strands are displaced, Cy5
on the 5′ blocking strand is separated from Cy3 on the 3′ end of the capture strand, and excitation
with a 543 nm green HeNe laser now results in direct emission of Cy3 rather than Cy5 FRET
signal (Figure 2.2). Additional 405 nm scans are repeated until no further changes in Cy3-Cy5
FRET are observed, with overall photolysis durations typically lasting a few minutes at most.
Once maximal loss of FRET (>60%) is achieved in the target cell, its mRNA is considered
labeled, and a small region containing the target cell is isolated out of the resected tissue slice
using patch-pipette aspiration. From there, the cell is lysed by a high salt buffer and freeze-thaw
cycle, cDNA is created by reverse transcription, and the cDNA pool is prepared for sequencing by
linear amplification and barcode addition. While this process still requires the use of patch-pipette
aspiration to complete, it significantly reduces the mechanical dexterity required to cleanly isolate
a single cell, even allowing for isolation of single cells from resected brain slices. Additionally,
because the mRNA labeling step occurs prior to aspiration, it is generally thought that mechanical
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perturbations from the aspiration process may have less effect upon the transcriptome. However,
this assumption relies upon TIVA being present in sub-stoichiometric amounts relative to mRNA,
such that all photoactivated TIVA is immediately bound to mRNA and unavailable to bind to
mRNA generated in response to the aspiration process. This consideration will be discussed
further in the Future Directions section at the end of the thesis.

Synthesis and storage improvements
Upon my joining the TIVA project in 2013, the probe was already designed and
undergoing evaluation relative to traditional patch-pipette methods. However, due to the
impossibility of directly comparing single cell aspiration methods on the exact same control cells,
a large number of cells needed to be processed to assess the quality of the isolated
transcriptomes while accounting for single cell heterogeneity. Each experiment required ~3 nmol
of TIVA probe and probe yields were wildly inconsistent due to the unprecedented number of
non-canonical-base modifications combined into one probe. These modifications suffered from
lowered coupling rates, and each modification decreased the overall yield. At best, a solid-phase
synthesis batch provided 20 nmol of moderately pure probe per 1 micromole-scale synthesis, but
at worst syntheses would abort mid-sequence due to coupling rates falling below 85%. Every
synthesis generated a different distribution of failed sequences and a product peak with a
different shape and retention by RP-HPLC (Figure 2.3), presumably due to the presence of
impurities that were difficult to detect with the imprecise “broad-peak” characterization of
MALDI-MS used at the time. To meet the needs of our collaborators, I endeavored to improve the
synthesis of the TIVA probe to achieve a product with reliably high purity and yield.
In brief, most of the issues could be traced back to errant environmental photolysis of
nitrobenzyl groups or moisture competing with monomer addition during solid-phase synthesis.
Synthetic work was previously conducted in a laboratory that was dimly illuminated by sunlight
through semi-transparent curtains. While this limited lighting helped to reduce photolysis of
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nitrobenzyl groups relative to a fully illuminated lab, low-intensity UV light was still being cast
upon benchtop samples for several hours every day. To remedy this issue, our lab was covered
with blackout curtains and all illumination was provided by red LED light strips (Tasodin
B01HRMPBQQ, approx. 620-640 nm), or red-filtered headlamps. Additionally, all computer
monitors in the lab were covered by orange or red plastic filters. Excluding water from the
synthesis was more complicated. During solid-phase synthesis, water molecules compete with
the 5′ hydroxyl group of the growing oligo chain for nucleophilic attack on the incoming activated
monomer (Figure 2.4). Syntheses were most likely to fail on days when laboratory humidity
exceeded 40%, and as a result syntheses were scheduled to avoid days with high humidity
whenever possible. Naturally, this lead to decreased productivity, lower yields, and more
complicated purifications during the humid summer months. To remove as much moisture from
the synthesis as possible, a number of steps were taken. First, a “glovebox-like” tent was
constructed from static-reducing, heavy plastic sheeting around the synthesizer, with a
dehumidifier running constantly to keep the internal humidity below 30%. This allowed us to
perform more reproducible syntheses year-round. Additionally, a more rigorously anhydrous
phosphoramidite (“amidite”) preparative procedure was implemented: frozen amidite bottles were
thawed in a dry chamber and subsequently dissolved with freshly-opened anhydrous acetonitrile
at <10 ppm H2O. The contents were then mixed by gentle inversion for ~30 seconds before being
loaded directly onto the synthesizer shortly before incorporation. If necessary, syntheses were
broken up into 4-5 sub-sequences so that amidites were in solution (and thus vulnerable to
hydrolysis) for the shortest time possible rather than waiting on the instrument. Previously,
amidites were thawed on the bench, dissolved with semi-anhydrous acetonitrile with varying
degrees of freshness, harshly vortexed for ~1 minute to dissolve the contents, and then loaded
onto the synthesizer en masse at the start of a 10+ hour synthesis. The resulting amidite
hydrolysis likely played a large part in the poor and irreproducible results previously observed.
Finally, we moved from 16% 1-methylimidazole to 6.5% dimethylaminopyridine (DMAP) as our
secondary capping reagent, which is reported to improve capping rates and reduce deletion
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mutants during long syntheses (Glen Research, 2018). This was important to us because
repeated couplings of the same monomer (as in our poly(A)/(U) sequences) are especially
vulnerable to capping failures. After implementing these improvements to background
illumination, water exclusion, reagent handling, and capping reagent, reproducible syntheses
became possible (Figure 2.5), typically yielding 20-50 nmol of TIVA at >90% purity per 1
micromole-scale synthesis.
Finally, changing the TIVA probe storage solution from nuclease-free water to 1x STE
buffer extended the shelf life of the probe from 3 months to ~1 year, even for storage at -20°C
with frequent freeze-thaw cycles. We initially characterized a version of the probe lacking pendant
CPP after synthesis in October 2015, and then re-visited its characterization in February 2016
and again in August 2016. To examine the structural integrity of the probe we assessed its purity
by RP-HPLC and measured its mass by ESI-MS. RP-HPLC separation of the 1 year old product
revealed the introduction of a small potential impurity at ~13 minutes that lacked Cy5 absorption,
possibly corresponding to a small amount (<5% by area) of photolysis or hydrolysis of the
hairpin-turn PCL over time (Figure 2.6). However, the presence of photolyzed capture strand was
not visible by ESI-MS, which revealed only the intact probe at 12,587 Da as well as a minor
impurity of a -U deletion mutant that is common in TIVA syntheses, difficult to resolve, and
functionally analogous to the parent compound (Figure 2.7). To assess the integrity of the hairpin
duplex we remeasured the probe Tm and FRET efficiency. The Tm showed a minor decrease from
56.4°C in February 2016 to 54.5°C in August 2016 (Figure 2.8), and the FRET efficiency of
unphotolyzed probe alone in buffer exhibited a gradual decrease from 92.3% 87.4% over one
year (Figure 2.9). It is possible that a rehybridization procedure involving 80 °C thermal
denaturation followed by slow cooling could restore hairpin annealing. However, this procedure
has had mixed results on TIVA probes, occasionally increasing aggregation between molecules,
especially in constructs with (D-Arg)9. For this reason we typically recommend against
rehybridization procedures unless the probe shows significant loss of FRET. Nonetheless, these
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experiments confirmed that the probe maintained excellent shelf-life from October 2015 to August
2016 when stored in 1x STE buffer.
With improved synthesis and storage protocols in place, revisions were quickly
completed on our 2014 proof-of-principle paper (Lovatt et al., 2014). In this work, we
demonstrated that TIVA could be delivered into hippocampal brain slices and selectively activated
in pyramidal neurons, as well as fibroblasts and cardiomyocytes (Figure 2.10b). Labeled,
high-FRET cells could then be activated with a 405 nm laser to observe a resulting decrease in
FRET corresponding to mRNA binding (Figure 2.10c). mRNA from cells that were photoactivated
and amplified produced visible band smears covering the lengths of common mRNAs on microgel
analysis, whereas unactivated neighboring cells exhibited minimal signal (Figure 2.10d). Lastly,
TIVA was shown to capture transcripts that were comparable in number (Figure 2.10e) and
complexity (Figure 2.10f) to patch-pipette aspiration alone.

Collaborations
The 2014 TIVA paper has been highly cited (133 times as of 10/19/2018, Google Scholar)
and created significant interest in the TIVA technique. As a result, many (>10) labs around the
world expressed enthusiasm in establishing collaborations to utilize TIVA probes in new and
exciting ways. Hongkui Zeng, executive director of structured sciences at Allen Institute of Brain
Science

in

Seattle,

was

interested

in

integrating

TIVA into neuronal imaging and

connectivity-mapping studies. These applications were closely aligned with our initial validation
with the Eberwine lab, and seemed like a great way to establish third party validation of our
existing methods. Margaret Scull, a postdoctoral student in the Rice lab at Rockefeller University,
was interested in using TIVA to study virus production in cultured cells. Scott Fraser, at the
University of Southern California, wanted to apply TIVA to the study of bobtail squid, in particular
examining the squid’s symbiosis with the bacteria of its light organ, the Vibrio fisherei. Both the
host and resident bacteria undergo transcriptomic changes upon their initial meeting during early
development, and TIVA was uniquely positioned to capture mRNA from this system. Andrew Allen
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at the University of Melbourne, Australia was looking at how the brain generates vasomotor
activity,

specifically

aiming

to

identify

new

neurochemical

markers

specific

to

non-catecholaminergic neurons using TIVA. Yutaka Uchida in the Ichii lab at Osaka University,
Japan, aspired to apply TIVA to intravital multiphoton microscopy studies in living mouse brain.
Both the Allen and Ichii labs were able to obtain grant funding from their respective national
science foundations to apply TIVA probes to their experimental design. The Kulesa lab at Stowers
Institute wished to use TIVA to track the migration and behavior of human neuroblastomas
grafted into the chick neural crest environment. Finally, Amgen was interested in licensing the
TIVA probe. By following our protocol for TIVA synthesis, Amgen was able to follow create TIVA in
high enough yields and purities to use for their own independent assessment of in vivo function.
Over the next couple years (2014-16) I spent a considerable amount of time supplying
these labs as well as our local collaborators with TIVA probe. Many of these collaborations went
silent without communicating any findings. Margaret Scull successfully delivered TIVA to cultured
cells while maintaining a high FRET ratio, photoactivated a target cell in the middle of the plate,
and observed a corresponding FRET change. However, without a good patch-pipette setup she
endeavored to lyse the entire plate of cells, with one activated cell among thousands ‒ in theory,
this should still result in the selective pull-down of the single activated cell’s mRNA. In practice,
she observed high background signal (data not shown), pointing to potential limitations in hairpin
caging efficacy. A number of collaborators had difficulty delivering the TIVA probe and gave up
after experimenting with a few other delivery methods. Such difficulties were expected in the more
ambitious whole organism applications such as Yukata Uchida’s, but difficulties delivering TIVA
into common cultured cell lines were more surprising. All CPPs exhibit certain cell-type
dependencies in their delivery, likely based upon how compatible their particular charge and
hydrophobicity are with a given cell’s membrane lipid composition ‒ for example, a cationic CPP
like our (Arg)9 may fail to associate with a membrane that lacks a sufficient density of negatively
charged phospholipids (Madani et al., 2011). However, examples of successful TIVA uptake in
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collaborators’ hands were rare. Only one collaboration, with the Kulesa lab, yielded any
actionable results. These will be discussed further in Chapter 3.
After two years of supporting collaborations, we had little data to show for it and more
questions than answers. To some extent, it was reasonable to accept that these collaborations
had simply failed due to the immense amount of materials, instrumentation, and technical
expertise required for TIVA experiments. For the cell labeling and isolation procedure alone, most
experiments required specialized knowledge on cultivating model organisms and ressecting
target tissue slices, a laser scanning confocal microscopy setup with 405 nm and ~543 nm laser
lines, heated stage, and a micro-manipulator-controlled patch-pipette, and both the microscopy
and cell culture facilities had to be illuminated by red light. After cell isolation the steps for
pull-down, amplification, and library preparation took roughly one week of full-time work, requiring
hundreds of unique molecular biology reagents and careful pipetting throughout the entire
procedure to ensure that signal was neither lost nor introduced falsely. For a TIVA experiment to
work well, the entire ~10 day protocol had to be completed smoothly. If establishing proficiency in
the TIVA method took multiple years to achieve in our own labs, it seemed almost unrealistic to
expect anyone in an outside lab to achieve similar results in a shorter time frame. Still, our failure
to establish additional collaborations motivated us to re-examine several key aspects of TIVA
performance: delivery, nuclease stability, and caging integrity. Each will be discussed in the
coming chapters.
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Figure 2.1 Structural scheme of first-generation, 18/7/7 (D-Arg)9 TIVA probe.
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Figure 2.2 Cartoon scheme of TIVA function. The intracellular reducing environment removes the
disulfide-linked (D-Arg)9 cell-penetrating peptide. Photolysis in the target cell by 405 nm laser cleaves the
o-nitrobenzyl linkers (“hν” locks below), allowing the poly(A) tail of mRNA to displace the shorter poly(A)
blocking strands. Dissociation of the blocking strands separates Cy5 (red orb) from Cy3 (green orb),
resulting in a shift from Cy5 FRET to Cy3 emission when excited with 543-nm laser. Probe-bound mRNA
can then be isolated via lysis and streptavidin affinity-purification utilizing the biotin moiety on the end of the
poly(U) capture strand.
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Figure 2.3 RP-HPLC purification of three different 18/7/7 TIVA probe syntheses prior to protocol
improvements. Separation was performed on a C-18 column under a gradient of increasing acetonitrile in
0.5 M TEAA, with the product eluting at roughly 51 min.
(Originally published in S.B. Yeldell et al. Org. Biomol. Chem. 2017, 15 (47), 10001–10009.)
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Figure 2.4 Mechanism for the coupling stage of oligonucleotide synthesis via solid-phase phosphoramidite
chemistry. Nucleophilic attack of the activated phosphorous by the growing oligo chain 5′ hydroxyl group can
undergo competition with any water present, highlighting the need for rigorously anhydrous synthesis
conditions.
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Figure 2.5 RP-HPLC purification of three different 18/7/7 TIVA probe syntheses after protocol
improvements, resulting in more consistent syntheses with higher yield. Separation was performed on a
C-18 column under a gradient of increasing acetonitrile in 0.5 M TEAA, with the product eluting at roughly 51
min.
(Originally published in S.B. Yeldell et al. Org. Biomol. Chem. 2017, 15 (47), 10001–10009.)
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Figure 2.6 RP-HPLC separation of an 18/7/7 TIVA probe lacking the 5′ disulfide-linked (D-Arg)9. Separation
performed on a C18 column at 40 °C in a gradient of 0.5 M TEAA buffer with increasing acetonitrile.
Leftmost trace shows original October 2015 purification of crude mixture after synthesis and cleavage from
CPG, with product eluting at ~34 min. Middle trace shows reinjection of purified material in February 2016,
and rightmost trace shows reinjection of same material in August 2016.
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Figure 2.7 ESI-MS analysis of 18/7/7 TIVA probe lacking the 5′ disulfide-linked (D-Arg)9 peptide.
Measurements were performed in February 2016 and August 2016, with no significant change observed.
The product was identified with a mass matching the expected value of 12,587 Da.
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Figure 2.8 Thermal melting point analysis of 18/7/7 TIVA probe lacking the 5′ disulfide-linked (D-Arg)9
peptide. Measurements were performed on a Beckman Coulter DU800 UV-Vis spectrophotometer with
programmable Peltier temperature controller. Samples were suspended at 1 μM in 1x STE buffer, and were
subjected to a thermal gradient of 0.5 °C/min with forward and reverse melts collected. Two trials were
collected for February 2016 (light and dark orange), and one trial for August 2016 (purple).
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Figure 2.9 Cy3-Cy5 FRET emission spectra for 18/7/7 TIVA probe lacking the 5′ disulfide-linked (D-Arg)9.
Probes were measured alone at 1 μM in 1x STE buffer for October 2015, February 2016, and August 2016.
Calculated FRET approximations were based upon donor excitation at 543 nm and acceptor emission at
667 nm.
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Figure 2.10 (a) Schematic of the experimental steps for TIVA probe mRNA isolation and analysis. (b)
Fluorescence photomicrographs showing uptake of (D-Arg)9-labeled TIVA tag by indicated cell types after
the entire area of the cell was photoactivated using the 405 nm laser line. Scale bar, 20 μm. (c)
Fluorescence intensity for the cells in (b), showing the photoactivation of TIVA probe by loss of FRET signal
with a simultaneous increase in Cy3 fluorescence and decrease in Cy5 fluorescence. (d) Bioanalyzer
microgel image analysis showing amplified RNA (aRNA) from coverslips with and without a photoactivated
cell. (e) Number of expressed transcripts in single neurons or in bulk samples, defined as those with greater
than ten unique exon reads per transcript using normalized RNA-seq data (n = 3 neurons for pipette
isolation and n = 4 neurons for TIVA-probe isolation; error bars, s.d.) (f) Heatmap of Spearman correlation
coefficients among single cells collected with pipette or TIVA probe,, performed using normalized log2
read-count data.
(Originally published in Lovatt et al. Nat. Meth. 2014.)
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Chapter Three
Adapting TIVA towards whole organism experiments

Partially adapted from:
S.B. Yeldell et al. Org. Biomol. Chem. 2017, 15 (47), 10001–10009.
In collaboration with:
Paul Kulesa*
Jason Morrison*
Cathy McKinney*
*Stowers Institute for Medical Research
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Introduction
An important goal of the TIVA project is to advance from the study of single cells in
resected tissue slices to single cells labeled in whole organisms, with the ultimate motivation of
clinical applications in human patients. While the original “18/7/7” TIVA probe was shown to be
capable of isolating mRNA from cells in ex vivo tissue slices, advancing to the study of single
cells in whole, living organisms presents a multitude of challenges. As discussed in Chapter 2,
most cell-penetrating peptides are not sufficiently universal to deliver TIVA into all cell-types in a
tissue region. As we move into deeper, less accessible tissue regions it becomes more difficult to
monitor the FRET pair and to activate and extract the target region. Investigation of both of these
challenges, however, is ultimately bottlenecked by the stability of the probe itself. In particular, the
TIVA probe must remain intact and inactive (“caged”) through longer time courses in more harshly
degrading, nuclease-abundant conditions.
Hamburger Hamilton chick embryos present an ideal stepping stone from resected tissue
to whole organism studies due to their accessible small size, optical transparency, and application
as a model for development and disease. Collaborators Paul Kulesa, Jason Morrison, and Cathy
McKinney at the Stowers Institute for Medical Research are utilizing the chick embryo model to
investigate the mechanisms by which tumor cells interact with their local microenvironments to
undergo remodeling and invasive metastasis (Kulesa et al., 2013). They’ve suggested that
melanoma and neuroblastoma cells may hijack parts of the neural crest genetic code to do so:
neural crest cells are highly migratory during development, utilizing environmental cues to
spatially sculpt their invasion and segregation during their movement to peripheral targets (Kulesa
and Gammill, 2010). One way to better understand this connection between neural crest cells and
cancer cell programming is to observe the migration, interactions, and transcriptomic profile of
human neuroblastoma cells transplanted into the chick embryo neural crest. The need for
spatiotemporal

control, fluorescent labeling, microenvironmental context, and complete
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transcriptome capture in this study make TIVA a potentially ideal approach if limitations to probe
delivery and nuclease stability can be overcome.
Here, we report variations of the original “18/7/7” TIVA probe that are built around
lengthened hairpins, extended to as far as a 22mer polyU capture strand with two 9mer polyA
blocking strands (“22/9/9”). This lengthened duplex was incorporated to improve probe thermal
stability pre-photolysis and to increase mRNA capture affinity post-photolysis. We then explored
the stronger serum stability and enhanced cellular uptake mediated by a phosphorothioate (PS)
backbone in developing the “PS-22/9/9” probe (Figure 3.1). By replacing a non-bridging backbone
phosphodiester oxygen with a sulfur atom at each linkage, the oligo can be made more resistant
to degradation by a variety of nucleases and phosphodiesterases. In general, phosphorothioation
disrupts oligo interactions critical for coordination of these degratory enzymes by adding chiral
centers to each backbone linkage, thereby increasing structural variation (Fica et al., 2013;
Frederiksen et al., 2012; Verma and Eckstein, 1998; Zhang et al., 1999).

Experimental methods
Synthesis of PS-22/9/9 TIVA probe
TIVA probe production was conducted using phosphoramidite chemistry in a room
illuminated by red lights (Tasodin B01HRMPBQQ, approx. 620–640 nm). The initial automated
synthesis was performed at a 1 μmol scale on an ABI 394 synthesizer according to manufacturer
instructions except where noted. Phosphoramidites (Glen Research, Sterling, VA) were thawed in
a desiccator for 10 min prior to use. To limit the time spent on the instrument by
moisture-sensitive modifier phosphoramidites prior to coupling, the syntheses were split into
segments such that modifiers were loaded onto the instrument immediately prior to use. Coupling
efficiencies were further improved by dissolving the amidites in rigorously anhydrous acetonitrile
(<10 ppm H2O), changing coupling reagents weekly, allowing couplings to proceed for 6 min, and
performing syntheses in a chamber dehumidified to <35% atmospheric humidity.
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After solid-phase synthesis of TIVA probe, the oligo was deprotected with the DMT group
left on and cleaved from the support in 1.3 mL concentrated ammonium hydroxide at rt for 16–18
h. The ammonium hydroxide was then removed by venting for 1 h followed by drying under mild
vacuum at rt for 50 min. The support was washed four times with 750 μL of 50:50
water:methanol, and the collected oligo solution was syringe filtered to 0.2 μm. The DMT-off
product was isolated by reverse-phase (RP) HPLC (Agilent 1100S) on a C18 column at 1.0 mL
min−1, 40 °C. A gradient of increasing acetonitrile (B) in 0.1 M TEAA (A) was employed for
purification: 30% B to 40% B over 30 min, increasing to 90% B in 5 min, sustaining at 90% for 3
min, then dropping to 10% over 8 min, with the product eluting at ∼27 min based upon monitoring
of nucleobase (254 nm), Cy3 (552 nm), and Cy5 (643 nm) absorbances (Figure 3.2), and a yield
of 190 nmol (19% yield) was determined based upon A260 (ε = 463,000 L (mol cm)−1 estimated
via idtdna.com/calc/analyzer) and starting scale of 1.0 μmol. No further CPP conjugation was
necessary. Isolated PS-22/9/9 TIVA probe was buffer exchanged into STE storage buffer (10 mM
Tris-HCl, 1 mM EDTA, 100 mM NaCl) using 10k MW cutoff Ultra-4 cellulose spin columns
(Amicon) in an Eppendorf centrifuge (5810 R) cooled to 4 °C. After complete buffer exchange the
probe was washed four additional times with ice-cold STE buffer and spun to a final concentration
of 100 μM. Finally, the TIVA probe was separated into 3.0 nmol aliquots and stored at −20 °C.

Mass determination
Oligonucleotide masses were determined by Novatia, LLC using a LC-MS system with
electrospray injection (Oligo HTCS). For the PS-22/9/9 probe the product was observed at
15,898.9 Da in addition to a minor +15 Da adduct likely corresponding to an unremoved
cyanoethyl group. (Figure 3.3).

Tm and FRET sample preparation
Four 60 μL (FRET) or 250 μL (Tm) TIVA probe samples were prepared at 1.0 μM in 1×
STE buffer: two samples mixed with one equivalent of 30mer polyA 2′-OMe RNA as a model
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polyA tail (“+polyA”) and two samples without polyA RNA (“−polyA”). One −polyA and one +polyA
sample were then photoactivated (“+hν”), while the remaining two samples were left unactivated
(“−hν”). Photoactivation was performed using a TL-355R Ultraviolet Transilluminator (Spectroline,
Westbury, NY), irradiating the samples at 365 nm, 9 mW cm−2 for 8 min, followed by brief mixing,
and then irradiating for an additional 8 min. Finally, the samples were incubated at 37 °C for 5 min
and then cooled to rt.

Melting point determination
The thermal stabilities of TIVA probe samples were assessed using a Beckman Coulter
DU800 UV-Vis spectrophotometer and Peltier temperature controller. Samples were heated at 1.0
°C min−1 from 15 °C to 90 °C, held at 90 °C for 10 min, and then cooled at 1.0 °C min−1 from 90 °C
back to 15 °C, and A260 was measured each minute. Tm values were assigned to each phase
using first-derivative analysis.

FRET measurement
Cy3–Cy5 FRET emission was measured on a Cary Eclipse fluorimeter (Varian) with Cary
Temperature Controller (Agilent) set to 20 °C. Cy3 was excited at 552 nm and the emission
spectrum was collected from 555–705 nm. FRET efficiency was approximated using the formula
FRET = Ia/(Ia + (Id × γ)), where Ia is the emission intensity of the FRET acceptor at 665 nm, Id is
the emission intensity of the FRET donor at 565 nm, and γ is a correction factor of 2.0 for the two
fluorophores’ differing quantum yields. We chose to utilize this approximation method over more
complex photobleaching or single-fluorophore probe methods as it can also be used to estimate
the FRET signal from TIVA probe in real-time microscopy applications.

Fluorimeter-based stability assay
Phosphorothioated (PS-22/9/9) or phosphodiester (22/9/9) TIVA probes were diluted to
1.0 μM in PBS with 10% FBS and incubated at 37 °C for 24 h in a Cary Eclipse fluorimeter. Cy3
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emission at 565 nm and Cy5 emission at 665 nm were recorded every 5 min for the first hour and
then every 20 min for hours 2–24. FRET efficiencies were approximated as previously noted, and
these values were then normalized against their respective starting values to depict the relative
change in FRET over time for each probe.

Gel-based stability assay
PS-22/9/9 and 22/9/9 TIVA probes were prepared as 250 μL, 1.0 μM solutions in 90%
PBS/10% FBS and incubated at 37 °C for 48 h. Aliquots (40 μL) were collected and snap-frozen
in liquid nitrogen at 0, 2, 4, 8, 24, and 48 h. Each aliquot was then purified by an RNeasy Mini Kit
(Qiagen) before drying to a pellet and redissolving in 5 μL of formamide. Each sample was then
mixed with 1.0 μL loading buffer before running on a 7.0 M urea polyacrylamide denaturing gel at
300 V for 30 min. Gels were imaged for Cy3 and Cy5 fluorescence on a Typhoon FLA 7000 laser
scanner (GE).

Fibroblast cell culture and confocal microscopy
CCD-1112Sk human neonatal foreskin-derived fibroblasts (ATCC, Manassas, VA) were
cultured in IMDM with 10% FBS and penicillin/streptomycin in a 37 °C incubator with 5% CO2. For
microscopy experiments split cells were seeded onto P35GC-1.5-14-C 35 mm Petri dishes with a
14 mm glass microwell (MatTek Corporation, Ashland, MA) and cultured for an additional 24 h to
reach 70–90% confluency. At T0 the dishes were washed twice with DPBS and replaced with
fresh serum-free media containing 0.5 μM PS-22/9/9 or 22/9/9 TIVA and then returned to the
incubator. At 1.5, 6, and 24 h the dishes were removed and imaged using a Fluoview FV1000
inverted confocal microscope (Olympus) with a 1.30 NA UPLFLN 40× oil objective (Olympus),
and 543 nm green HeNe laser. Images were collected for both Cy3 emission (555 nm–625 nm
bandpass filter) and Cy5 FRET emission (650 nm long-pass filter).
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Embryo studies
Embryos were prepared as previously described (Kulesa et al., 2008) from fertilized
White Leghorn chicken eggs (Phil’s Fresh Eggs, Forreston, IL) incubated at 37°C in a humidified
incubator until the appropriate stages. Embryos were staged according to well established
staging criteria (Hamburger and Hamilton, 1951). TIVA was thawed on ice & re-hybridized (80C
for 30 min followed by 10 min on ice) and injected at shipped concentration (100-115um) into the
lumen of 10 chick embryos between 6 and 8 somite stage (HH9; n=10). Additional TIVA solution
was mixed in a 3:2 ratio with mTurquoise2 circular DNA plasmid (in water) which will express a
blue fluorescent protein. The mixture was injected into the neural lumen and electroporated using
usual chick protocols (HH9; n=11) (McLennan and Kulesa, 2007). TIVA and the embryos were
shielded from light until imaging.
Time-lapse confocal imaging was performed as originally described (Kulesa and Fraser,
1998), with minor modifications. Briefly, whole chick embryo explants were visualized using an
inverted confocal microscope (LSM 510 NLO and LSM 5 Pascal; Carl Zeiss MicroImaging,
Thornwood, NY) with either a 10× NA=0.3 or 0.45 objective (Carl Zeiss). Embryos were examined
3 hours after delivery for TIVA labeling. Imaged again at 5 hours, mTurquoise2 could be
visualized with the TIVA. And imaged again at 24 hours. All imaging took place on a confocal
microscope using 514nm and 633nm to image and 405nm to uncage. 2 types of images were
taken: Spectral and Channel (or regular) images. Spectral images allowed for observation of a
peak shift or a closer look at the emission/FRET of the Cy3/Cy5 pair. Channel images collected
emission from 543-629 for Cy3 and 644-759 for Cy5.
Photoactivation of TIVA probe was performed under a 20x 0.8NA or 40x 1.2NA objective
to zoom in on a single cell and scan in 2D using 16bit depth, 1024x1024 pixels and 0.74us dwell
time. Simultaneous scanning was performed with both the 405nm laser (30 mW) for uncaging
and 514nm laser to image Cy3 and Cy5 emission wavelengths as described above. The laser
power used varied with the TIVA probe version and biological sample. Some samples with later
versions of TIVA used less power (1% or less) but with the first early versions of the probe, higher
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powers were used (up to 30%). Uncaging scans were repeated until Cy3 photobleaching was
observed. After uncaging, a final image was captured using the same parameters as the before
image, and the intensity changes of Cy3 and Cy5 were compared. Using the lambda scan, final
FRET efficiencies of ~0.3 FRET or less were observed.

Results
As a baseline experiment, the Kulesa lab delivered first-generation, 18/7/7 TIVA probe
into the lumen of E5 chick embryos using either electroporation or a disulfide-linked (D-Arg)9
cell-penetrating

peptide.

Both

methods

broadly

labeled

the

target

cells,

although

(D-Arg)9-mediated uptake resulted in punctate signal immediately after uptake, whereas
electroporated TIVA remained evenly distributed in the cytoplasm for ~1 h prior to aggregation. All
cells were low-FRET within ~1 h, potentially corresponding to swift nuclease-mediated
degradation of 2′F/2′-OMe RNA probe (data not shown). To combat aggregation issues, a fresher
batch of 18/7/7+(D-Arg)9 probe was prepared and shipped in 1x STE buffer rather than dried
down. This batch exhibited even cytosolic signal for ~3 h rather than ~1 h when injected into the
lumen, and showed specific regions of high-FRET within the first 3 h (Figure 3.4). However, by 8
h post-injection low-FRET signal dominated (Figure 3.5). To extend the experimental window we
tested probes with longer duplexes (from 18mers to 22mers), as well as 22mer probes with
covalently-attached cell-penetrating peptides, all of which suffered from similar issues with low
FRET and eventual punctate clustering (data not shown). These results indicated that more
robust oligonucleotide modifications were required.
To improve the nuclease resistance of the TIVA probe we phosphorothioated each
backbone linkage, a well-established method for extending the serum stability of oligonucleotides.
Phosphorothioated antisense oligos have been utilized in an assortment of antisense treatments
(Karpuj et al., 2007; Kocisko et al., 2006; Zell et al., 2007), and this general topic has been
reviewed recently by Frick Eckstein (Eckstein, 2014). We determined that backbone sulfurs
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competed with the 5’ thiol modification for conjugation with (D-Arg)9 peptide, and we subsequently
omitted the CPP from further PS-oligo designs. PS-22/9/9 TIVA probe (Figure 3.1) was
synthesized

by

solid-phase

phosphoramidite

chemistry

as

previously

described

for

first-generation TIVA probe with slight modifications: during solid-phase synthesis the oxidation
step was replaced by a sulfurizing step prior to capping, and the final monomethoxytrityl group
was removed prior to cleavage. An “MMT off” purification was selected due to the stubbornly
reversible association of the trityl group with Cy5 when removed in solution, and relative ease of
removing the trityl group on solid phase. After solid-phase synthesis, the oligo was cleaved and
RP-HPLC purified with the DMT group off on an expanded gradient (Figure 3.2). Following HPLC
purification, PS-22/9/9 TIVA probe was buffer exchanged into 1x STE and concentrated to 100
µM as previously described and stored at -20 °C.

PS-22/9/9 TIVA general characterization
Product was characterized by ESI-MS (Novatia), which confirmed the expected 15,900
Da product with an observed 15,899 Da peak (Figure 3.3a). PS-22/9/9 TIVA probe purity was
gauged by RP-HPLC, and found to be roughly 90% (Figure 3.3b). Thermal melt analysis showed
that phosphorothioation significantly decreased the thermal stability of the duplex (Tm = 48 °C),
although the RNA target-bound Tm was less affected at 52 °C (Figure 3.3c). This hybridization
penalty has been well documented (Kibler-Herzog et al., 1991), and some groups have attempted
to limit the penalty by reducing the number of sites that are phosphorothioated (Damha et al.,
1998; Seth et al., 2012). In this case, PS-22/9/9 TIVA probe Tm values likely remain high enough
for in vivo applications at 37 °C.

Fluorescence and stability assessment
The FRET efficiency of PS-22/9/9 TIVA probe was first measured in a cuvette as
previously described in Chapter 4 for 22/9/9 GC (Figure 3.6a). The decreased starting FRET
(75%) is primarily explained by the lack of cationic CPP, but the lower thermal stability imparted
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by phosphorothioation may also be a contributing factor. This value drops sharply in the presence
of 1 eq 30mer polyA RNA, but can be photoactivated to achieve a final FRET efficiency of 5%,
comparable to 18/7/7 TIVA probe. We noticed that the FRET efficiency of unphotolyzed PS-22/9/9
TIVA probe in the presence of 1 eq polyA RNA was enhanced by roughly 11% when conducting
the trials in PBS with 10% FBS compared to PBS alone (Figure 3.6b). Phosphorothioation has
been previously reported to enhance the binding of non-specific serum proteins to
double-stranded oligonucleotides (Liang et al., 2015). We hypothesize that such protein
interactions may further rigidify the duplex in the PS-22/9/9 TIVA probe.
To assess the serum stability of PS-22/9/9 probe relative to traditional phosphodiester
probe (22/9/9) we incubated both at 37 °C in PBS with 10% FBS while monitoring FRET for 24 h
using a fluorimeter. Afterwards, we normalized the FRET readings for both probes relative to their
starting efficiencies (Figure 3.7a). We observed consistent FRET signal in PS-22/9/9 for the
duration of the experiment, whereas 22/9/9 lost 40% of its starting FRET efficiency during 24 h
incubation.
To further verify that PS-22/9/9 was not being degraded by serum nucleases we
performed 48-h incubation, snap freezing aliquots at regular intervals. After 48 h, all PS-22/9/9
and 22/9/9 aliquots were purified with RNeasy spin columns and loaded onto a denaturing 7 M
urea, 20% polyacrylamide gel for electrophoretic separation over 30 min at 100 V. Afterwards the
gels were imaged for Cy3 and Cy5 fluorescence on a Typhoon imager (Figure 3.7b). 22/9/9
exhibited partial degradation as soon as 2 h, with nearly complete degradation by 48 h.
Conversely, PS-22/9/9 remained intact for the full 48 h incubation. The degradation of the 22/9/9
probe was likely mediated by a 3´ to 5´ exonuclease, the most common serum nuclease (Eder et
al.,

1991).

However,

the

enzyme

responsible

for

oligonucleotides has not been identified (Eckstein, 2014).

Uptake in plated cells
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degradation

of

phosphorothioated

In addition to improving nuclease resistance, phosphorothioation-enhanced oligo-protein
adsorption has also been reported to assist in oligo delivery. The mechanism by which this
modification increases cellular uptake is still under study, but is likely related to enhanced binding
to proteins such as albumin, which act as a cloak and escort the oligo through various endocytotic
pathways (Juliano et al., 2014; Liang et al., 2015). This feature is potentially attractive as a
method of delivering the probe, which lacks the 5´ CPP found in earlier TIVA constructs. We
investigated this effect by incubating human fibroblast cells with 0.5 µM PS-22/9/9 or 22/9/9,
without use of CPP or other delivery agent. Images of Cy3 and Cy5 FRET emission were
collected using an Olympus Fluoview F1000 inverted confocal microscope at 1.5 h, 6 h, and 24 h
(Figure 3.8). From these images we observed uptake of the phosphorothioated probe within 1.5
h, with FRET signals that remained constant throughout the 24 h experiment. Conversely, 22/9/9
was observed to remain predominantly in solution with limited fluorescence signal within cells and
significantly lower FRET signal after 24 h.

Application to embryos
After observing promising serum stability and uptake in benchtop experiments, PS-22/9/9
TIVA was next applied to chick embryos. Electroporation of PS-22/9/9 probe into the lumen of E5
chick embryos once again resulted in broad labeling of the target neural crest cells.
Phosphorothioation extended the duration of even cytosolic distribution from ~3 h to 4.5 h. More
impressively, high FRET duration was extended from 1 h to 24 h (Figure 3.9 left). Additionally,
labeled cells could be photoactivated with a 405 nm laser, generating a loss of FRET (Figure 3.9
right). By 8 h, however, signal was predominantly punctate and colocalized with Lysotracker
(Figure 3.10), likely indicating endosomal entrapment. While TIVA could still be photoactivated at
these later time points, the quality (and quantity) of mRNA captured would be suspect. Therefore,
the ideal experimental window for the PS-22/9/9 probe remains from 0 - 4 h. Even during this
initial window, however, samples that were processed by RTqPCR exhibited non-specific
background transcripts, indicating potential failures in caging integrity.
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Conclusions
In summary, we synthesized a phosphorothioated TIVA variant that was stable in the
presence of 10% serum for 48 h and exhibited unaided cellular uptake in human fibroblast cells.
The probe was successfully delivered into E5 Hamilton-Hambuger chick embryo neural tubes,
where it remained evenly distributed for up to 4.5 h and high FRET for 24 h. However, the
PS-22/9/9 probe was ultimately deemed inadequate for studying the migration of neuroblastomas
through the neural tube, due to the non-specific background transcripts that were observed by
RTqPCR as well as the experimental time limit of 4.5 h, which was insufficient to capture mRNA
throughout the ~24 h migration event. A summary of all probe variations and model systems
tested by the Kulesa lab can be seen in Table 3.1.
Non-specific background pull-down was likely worsened by the broad usage of
phosphorothioate modifications, which decrease the thermal stability of the duplex. This duplex
destabilization was already hinted at in the benchtop Tm and FRET assays, and did not appear to
be sufficiently offset by the stabilizing effect of serum protein adsorption. Therefore, if
phosphorothioation is utilized in future probes, additional measures must be taken to offset the Tm
penalty, such as including a hairpin-terminating GC pair. It may also be possible to achieve
exonuclease resistance by only phosphorothioating the terminal groups, or selectively
phosphorothioating interior groups against endonuclease activity only as needed according to
ESI-MS analysis of nuclease-digested samples. Alternative nuclease-resisting approaches will be
explored, such as employing peptide nucleic acids (PNAs) or other modified backbones to further
extend TIVA probe lifetime. Further investigation into hairpin caging efficacy and non-specific
background pull-down will be the focus of Chapter 4.

67

References
Damha, M.J., Wilds, C.J., Noronha, A., Brukner, I., Borkow, G., Arion, D., and Parniak, M.A. (1998). Hybrids
of RNA and Arabinonucleic Acids (ANA and 2‘F-ANA) Are Substrates of Ribonuclease H. J. Am. Chem. Soc.
120, 12976–12977.
Eckstein, F. (2014). Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid
Ther. 24, 374–387.
Eder, P.S., DeVine, R.J., Dagle, J.M., and Walder, J.A. (1991). Substrate specificity and kinetics of
degradation of antisense oligonucleotides by a 3’ exonuclease in plasma. Antisense Res. Dev. 1, 141–151.
Fica, S.M., Tuttle, N., Novak, T., Li, N.-S., Lu, J., Koodathingal, P., Dai, Q., Staley, J.P., and Piccirilli, J.A.
(2013). RNA catalyses nuclear pre-mRNA splicing. Nature 503, 229–234.
Frederiksen, J.K., Li, N.-S., Das, R., Herschlag, D., and Piccirilli, J.A. (2012). Metal-ion rescue revisited:
biochemical detection of site-bound metal ions important for RNA folding. RNA 18, 1123–1141.
Hamburger, V., and Hamilton, H.L. (1951). A series of normal stages in the development of the chick
embryo. J. Morphol. 88, 49–92.
Juliano, R.L., Ming, X., Carver, K., and Laing, B. (2014). Cellular uptake and intracellular trafficking of
oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther. 24, 101–113.
Karpuj, M.V., Giles, K., Gelibter-Niv, S., Scott, M.R., Lingappa, V.R., Szoka, F.C., Peretz, D., Denetclaw, W.,
and Prusiner, S.B. (2007). Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in
cultured cells. Mol. Med. 13, 190–198.
Kibler-Herzog, L., Zon, G., Uznanski, B., Whittier, G., and Wilson, W.D. (1991). Duplex stabilities of
phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers. Nucleic Acids Res. 19,
2979–2986.
Kocisko, D.A., Vaillant, A., Lee, K.S., Arnold, K.M., Bertholet, N., Race, R.E., Olsen, E.A., Juteau, J.-M., and
Caughey, B. (2006). Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides.
Antimicrob. Agents Chemother. 50, 1034–1044.
Kulesa, P.M., and Fraser, S.E. (1998). Neural crest cell dynamics revealed by time-lapse video microscopy
of whole embryo chick explant cultures. Dev. Biol. 204, 327–344.
Kulesa, P.M., Teddy, J.M., Stark, D.A., Smith, S.E., and McLennan, R. (2008). Neural crest invasion is a
spatially-ordered progression into the head with higher cell proliferation at the migratory front as revealed by
the photoactivatable protein, KikGR. Dev. Biol. 316, 275–287.
Kulesa, P.M., and Gammill, L.S. (2010). Neural crest migration: Patterns, phases and signals. Dev. Biol. 344,
566–568.
Kulesa, P.M., Morrison, J.A., and Bailey, C.M. (2013). The Neural Crest and Cancer: A Developmental Spin
on Melanoma. Cells Tissues Organs 198, 12–21.
Liang, X.-H., Sun, H., Shen, W., and Crooke, S.T. (2015). Identification and characterization of intracellular
proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res. 43, 2927–2945.
MMcLennan, R., and Kulesa, P.M. (2007). In vivo analysis reveals a critical role for neuropilin-1 in cranial
neural crest cell migration in chick. Dev. Biol. 301, 227–239.
Seth, P.P., Jazayeri, A., Yu, J., Allerson, C.R., Bhat, B., and Swayze, E.E. (2012). Structure Activity
Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals. Mol.
Ther. Nucleic Acids 1, e47.
Verma, S., and Eckstein, F. (1998). Modified oligonucleotides: synthesis and strategy for users. Annu. Rev.
Biochem. 67, 99–134.
Zell, S., Geis, N., Rutz, R., Schultz, S., Giese, T., and Kirschfink, M. (2007). Down-regulation of CD55 and

68

CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to
complement attack. Clin. Exp. Immunol. 150, 576–584.
Zhang, Y.L., Hollfelder, F., Gordon, S.J., Chen, L., Keng, Y.F., Wu, L., Herschlag, D., and Zhang, Z.Y. (1999).
Impaired transition state complementarity in the hydrolysis of O-arylphosphorothioates by protein-tyrosine
phosphatases. Biochemistry 38, 12111–12123.

69

Figure 3.1: Structural cartoon of phosphorothioated 22/9/9 TIVA (PS-22/9/9). All linkages are
phosphorothioated.
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Figure 3.2: RP-HPLC purification of crude PS-22/9/9 probe after solid-phase synthesis and cleavage.
Separation was performed on C-18 column under a gradient of increasing acetonitrile in 0.5 M TEAA, with
the product eluting at roughly 27 min.
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Fig. 3.3: (A) ESI-MS of product. 15,900 Da expected, 15,897 Da observed. (B) Re-injection of purified
PS-22/9/9 TIVA on RP-HPLC. (C) Melting curve analysis of PS-22/9/9 while caged (red), photolyzed (blue),
or photolyzed and RNA target-bound (green).
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Figure 3.4: Delivery of 18/7/7 TIVA probe into E5 Hamilton Hamburger chick embryo neural
lumen via electroporation. At 2.5 h post-injection signal is mixed between high and lower FRET
regions (left). Individual high-FRET cells can be selectively photoactivated (right).
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Figure 3.5: Delivery of 18/7/7 TIVA probe into E5 Hamilton-Hamburger chick embryo neural lumen

via electroporation after dorsal or sympathetic ganglia injection. At 8 h post-injection low FRET
signal dominates in most regions. “NT” = neural tube, “DRG” = dorsal root ganglia, “N” =
notochord.
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Figure 3.6: (A) Cy3-Cy5 FRET efficiency of 1 µM PS-22/9/9 TIVA probe in 1x STE buffer with or without 1
eq of 30mer polyA RNA target and/or photolysis. (B) Pre-photolysis FRET efficiency of PS-22/9/9 probe in
the presence of 1 eq of 30mer polyA RNA is enhanced in PBS with 10% FBS. Average and standard
deviation shown for three or more samples for each condition.
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Figure 3.7: (A) 24 h stability time course of 1 µM phosphorothioate-linked PS-22/9/9 (green) or
phosphodiester-linked 22/9/9 (red) TIVA probes in 10% FBS. Cy3-Cy5 FRET efficiencies were measured by
fluorimeter and then normalized against starting values. (B) 48 h stability time course of 1 µM PS-22/9/9
(bottom) or 22/9/9 (top) probes in 10% FBS using gel electrophoresis. At each time point a sample was
mixed with a nuclease inhibitor and flash frozen. After 48 h, all samples were loaded onto a 20% acrylamide
denaturing gel and eluted using 100 V for 120 min. Cy3 fluorescence is shown in green and Cy5
fluorescence in red.
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Figure 3.8: (A) 24 h uptake of 22/9/9 (left) and PS-22/9/9 (right) TIVA probes in cultured human fibroblasts.
Cy3 fluorescence is shown in green and Cy5 FRET signal in red.
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Figure 3.9: (left) HH15 embryo neural crest cells labeled with PS-22/9/9 TIVA. FRET remains high for 4 h
after uptake and TIVA can be photoactivated site selectively (right).
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Figure 3.10: Colocalization study of Lysotracker (blue), as well as Cy3 (green) and Cy5 (red) signals from
PS-22/9/9 TIVA in cultured neuroblastomas.
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Chapter Four
Reducing background pull-down of unactivated TIVA

Partially adapted from:
S.B. Yeldell et al. Org. Biomol. Chem. 2017, 15 (47), 10001–10009.
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Introduction
As discussed in Chapters 2 and 3, collaborations with external labs alerted us to potential
issues with incomplete caging in TIVA’s hairpin design. Although the issue seemed to be
exacerbated by phosphorothioation, it was plausible that traditional phosphodiester probes also
suffered from similar background capture. This issue was difficult to diagnose at first, as some
labs were hesitant to adopt the recommended red laboratory lighting, possibly conflating poor
caging with inadvertent environmental photolysis. Curiously, while performing benchtop FRET
characterization of first-generation TIVA, we observed the FRET efficiency of pre-photolysis TIVA
to decrease from 86% to 51% once 1 eq. of a poly(A) 30mer RNA was added, acting as a loose
model of a mRNA poly(A) tail. TIVA FRET signal in the presence of 30mer poly(A) RNA then
further decreased to 5% upon photoactivation (Figure 4.1), possibly indicating that the
pre-photolysis interaction of TIVA and poly(A) RNA didn’t completely displace the hairpin blocking
strands to the extent observed after photolysis. Because the Eberwine lab had previously
demonstrated minimal capture of mRNA from unactivated samples (Figure 2.10d), it seemed
likely that this partial interaction between unphotolyzed TIVA and its target didn’t have a high
enough affinity to survive the pull-down procedure washing steps and manifest as background
signal ‒ an in vitro effect that perhaps would not translate to in vivo results. However, careful
RTqPCR control experiments by the Kulesa lab renewed our interest in assessing the caging
efficacy of TIVA ourselves.
In this chapter I discuss my efforts to accurately assess and improve the pre-photolysis
inertness ‒ or caging ‒ of TIVA probes. To improve the caging of the hairpin we took a
lengthened, 22/9/9 duplex, added specific G:C pairs to improve alignment, incorporated a PEG
spacer into the hairpin turn, and finally added more adenosines to the blocking strand to better
cover the capture strand. The first iteration, 22/9/9 GC (Figure 4.2), offered modest improvements
to caging while a further revision, 22/12/8 (GC)2 (Figure 4.3), achieved near-ideal caging during
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bench-top tests. These probes were assessed by an array of assays including native gel
co-migration, FRET perturbation, and pull-down assays with cell lysate.

Experimental Methods
Synthesis of 22/9/9 GC +(D-Arg)9 TIVA probe
TIVA probe production was conducted using phosphoramidite chemistry in a room
illuminated with red light (Tasodin B01HRMPBQQ, approx. 620-640 nm). The initial automated
synthesis was performed at a 1 µmol scale on an ABI 394 synthesizer according to manufacturer
instructions except where noted. Phosphoramidites (Glen Research, Sterling, VA) were thawed in
a desiccator for 10 min prior to use. To limit the time that moisture-sensitive modifier
phosphoramidites spent on the instrument before coupling, the syntheses were split into
segments such that modifiers were loaded onto the instrument immediately prior to use. Coupling
efficiencies were further improved by dissolving the amidites in rigorously anhydrous acetonitrile
(<10 ppm H2O), changing coupling reagents weekly, allowing couplings to proceed for 6 min, and
performing syntheses in a chamber dehumidified to <35% atmospheric humidity.
After solid-phase synthesis of TIVA probe, the oligo was deprotected with the DMT group
left on and cleaved from the support in 1.3 mL concentrated ammonium hydroxide at rt for 16-18
h. The ammonium hydroxide was then removed by venting for 1 h followed by drying under mild
vacuum at rt for 50 min. The support was washed four times with 750 µL of 50:50
water:methanol, and the collected oligo solution was syringe filtered to 20 µm. The product was
then isolated by reverse-phase (RP) HPLC (Agilent 1100S) on a C18 column at 1.0 mL/min, 40
°C. A gradient of increasing acetonitrile (B) in 0.1 M TEAA (A) on a C18 column was employed for
purification: 30% B to 40% B over 30 min, 40% B up to 90% B over 5 min, 90% B sustained for 3
min, and then back to 10% B over 8 min. The product eluted at roughly 28 min, based upon
monitoring of base (254 nm), Cy3 (552 nm), and Cy5 (643 nm) absorbances (Figure 4.4), and a
yield of 150 nmol (15% yield) was determined based upon A260 (ε = 463,000 L/(mole·cm
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estimated via idtdna.com/calc/analyzer)) and starting scale of 1.0 µmol. After RP-HPLC
purification the 22/9/9 GC probe was prepared for conjugation to (D-Arg)9 through concentration
to 300-350 µM by vacufuge at rt, before splitting into 10 nmol aliquots and diluting to 30 µL each.
Sodium phosphate buffer (10 µL of 100 mM, pH 7.1) and 4 µL of TCEP (Thermo Scientific) were
added to reduce the disulfide bridge connecting the DMT group to the 5´ thiol modifier. This
reduction proceeded for 1 h at rt before eluting through Nap-10 column (GE Healthcare) to both
desalt the solution and remove cleaved alkyl-DMT groups.
After concentrating the eluent TIVA probe to 100 µM by vacufuge at rt, the CPP
conjugation was performed using 600 µL formamide (Fisher), 40 µL of 2.0 M TEAA (Glen
Research), and 80 µL of 1 µM Cys(Npys)-(D-Arg)9 peptide (AS-61206, Anaspec). The mixture
was vortexed briefly and the conjugation was allowed to proceed for 24-36 h at rt. Conjugated
probe was purified by anion exchange HPLC (Agilent 1100S, 1.000 mL/min, RT) using a
Resource Q column (GE Healthcare) with a gradient of 100% buffer A (20 mM Tris-HCl (pH 6.8),
50% formamide) and 0% buffer B (20 mM Tris-HCl (pH 6.8), 50% formamide, 400 mM NaClO4)
transitioning to 0% buffer A and 100% buffer B over 30 min. The conjugated product eluted at ~23
min, prior to unconjugated material at ~25 min (Figure 4.5). The final yield for the CPP
conjugation was 58 nmol (38%), for a total yield of 5.8% relative to the 1.0 µmol starting
synthesis, measured as previously described.
Isolated 22/9/9 GC +(D-Arg)9 TIVA probe was buffer exchanged into STE storage buffer
(10 mM Tris-HCl, 1 mM EDTA, 100 mM NaCl) using 10k MW cutoff Ultra-4 cellulose spin columns
(Amicon) in an Eppendorf centrifuge (5810 R) cooled to 4 °C. After complete buffer exchange the
probe was washed four additional times with ice-cold STE buffer and spun to a final concentration
of 100 µM. Finally, the TIVA probe was separated into 3.0 nmol aliquots and stored at -20 °C.

18/7/7 ±(D-Arg)9 and 22/9/9 ±(D-Arg)9 TIVA probes
Synthesis and characterization of 18/7/7 -(D-Arg)9, 18/7/7 +(D-Arg)9 and 22/9/9 TIVA
probes were performed as described previously (Lovatt et al., 2014; Ruble 2012). 22/9/9
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+(D-Arg)9 probe was synthesized as described for 22/9/9 GC +(D-Arg)9 but RP-HPLC of the
cleaved probe was performed on an older gradient: 10% B to 60% B over 40 min, 60% to 80%
over 10 min, with the product eluting at roughly 50 min. AX-HPLC of the CPP-conjugated 22/9/9
product was performed as described for 22/9/9 GC +(D-Arg)9. Overall yield was estimated to be
30 nmol for a 1.0 µmol scale synthesis (3% yield) by A260 (ε = 446,000 L/(mole·cm)).

Synthesis of 22/12/8 (GC)2 +(D-Arg)9 TIVA probe
22/12/8 (GC)2 +(D-Arg)9 TIVA probe was synthesized as described for 22/9/9 GC
+(D-Arg)9. 22/12/8 (GC)2 TIVA ran similarly on RP-HPLC after cleavage (Figure 4.6), and
exhibited similar separation by AX-HPLC after CPP conjugation (Figure 4.7). The final yield for
the CPP-conjugated product was ~20 nmol, for a total yield of 2% relative to the 1.0 µmol starting
synthesis, measured as previously described.

Mass determination
Oligonucleotide masses were determined by Novatia, LLC using a LCMS system with
electrospray injection (Oligo HTCS). For the 22/9/9 +(D-Arg)9 probe the product was observed at
16,912 Da (16,913.3 calculated), with a minor -U deletion product at -308 Da (Figure 4.8). For the
22/9/9 GC +(D-Arg)9 probe the product was observed at 17591.7 Da (Figure 4.9a). Minor +54 Da
and +27 Da adducts were also observed, potentially cyanoethyl groups as well as a cyanoethyl
half-mass deconvolution artifact due to oligo self-complementarity. Analysis of 22/9/9 (GC)2
+(D-Arg)9 verified an expected principal mass of 19,168.8 Da with an observed mass of 19,168.2
Da (Figure 4.10a). +31.2 Da, +59.7 Da, +167.8 Da, and +195.5 Da adducts were also identified,
likely corresponding to combinations of sodium, acetate, and HFIPA ions retained from the
purification or electrospray preparation process.
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Tm and FRET sample preparation
Four 60 µL (FRET) or 250 µL (Tm) TIVA probe samples were prepared at 1.0 µM in 1x
STE buffer: two samples mixed with one equivalent of 30mer polyA 2´-OMe RNA as a model
polyA tail (“+polyA”) and two samples without polyA RNA (“-polyA”). One -polyA and one +polyA
sample were then photoactivated (“+hν”), while the remaining two samples were left unactivated
(“-hν”). Photoactivation was performed using a TL-355R Ultraviolet Transilluminator (Spectroline,
Westbury, NY), irradiating the samples at 365 nm, 9 mW/cm2 for 8 min, followed by brief mixing,
and then irradiating for an additional 8 min. Finally, the samples were incubated at 37 °C for 5 min
and then cooled to rt.

Melting point determination
The thermal stabilities of TIVA probe samples were assessed using a Beckman Coulter
DU800 UV-Vis spectrophotometer and Peltier temperature controller. Samples were heated at 1.0
°C /min from 15 °C to 90 °C, held at 90 °C for 10 min, cooled at 1.0 °C/min from 90 °C back to 15
°C, and A260 was measured each minute. Tm values were assigned to each phase using
first-derivative analysis.

FRET measurement
Cy3-Cy5 FRET emission was measured on a Cary Eclipse fluorimeter (Varian) with Cary
Temperature Controller (Agilent) set to 20 °C. Cy3 was excited at 552 nm and the emission
spectrum was collected from 555-705 nm. FRET efficiency was approximated using the formula
FRET= Ia / (Ia+(Id*γ)), where Ia is the emission intensity of the FRET acceptor at 665 nm, Id is the
emission intensity of the FRET donor at 565 nm, and γ is a correction factor of 2.0 for the two
fluorophores’ differing quantum yields. We chose to utilize this approximation method over more
complex photobleaching or single-fluorophore probe methods as it can also be used to estimate
the FRET signal from TIVA probe in real-time microscopy applications.
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Streptavidin bead prep
Dynabeads (ThermoFisher Sci 65001) were first removed from 4 °C storage and warmed
on bench top for 30+ min to rt. Dynabeads were vortexed for 1+ min and an aliquot of X μL beads
(X = 150 μL per sample for GFP-poly(A) pull-down, later reduced to 50 μL per sample for cell
lysate pull-down) was removed to a LoBind 1.5 mL microtube (Eppendorf 022431021) and
washed three times on a magnetic stand using 1x BW buffer (prepared as 2x BW stock: 10 mM
Tris (pH 7.5), 1 mM EDTA, 2 M NaCl). Beads were fully resuspended and then allowed to settle
for at least 60 s on the magnetic stand for each wash. As a precaution against any contaminating
RNA, the beads were incubated with X μL 0.1 M NaOH, 0.05 M NaCl for 2 min, then set on the
magnetic stand for 1 min, and the wash was removed and then replaced for another 2 min
treatment. The beads were then similarly incubated twice for 2 min with X μL 0.1 M NaCl, and
then resuspended in the original volume of BW buffer. On the day of the pull-down experiment, to
block the beads against nonspecific hydrophobic interactions an additional X μL of 10 ng/μL
purified BSA and 0.1*X μL 1 M spermidine were added and the bead mixture was rotated for 1 h
at rt. After blocking, the beads were washed three times with 1x BW buffer, and then resuspended
in the original volume (X μL) of 1x BW buffer.

GFP-poly(A) expression, pull-down, and detection
To obtain GFP-poly(A) transcript, pRS314-T7-GFP plasmid (Addgene ID 33130) was
initially expressed in E. coli as described previously (Ping et al., 2017), and was subsequently
purified by Maxiprep (Thermo Fisher Scientific) and digested with XhoI restriction enzyme for 1 h.
Linearized pRS314-T7-GFP RNA was purified by QIAquick affinity columns (Qiagen), and then
T7-mediated in vitro transcription of the GFP gene was performed with a MEGAscript T7
Transcription Kit (Invitrogen) per manufacturer’s protocol. GFP transcripts were polyadenylated
with a Poly(A) Tailing Kit (Invitrogen AM1350) per manufacturer’s instructions (Figure 4.11). After
polyadenylation, GFP-poly(A) RNA expected 1.2-1.4 kb size was verified by capillary gel
electrophoresis (Figure 4.12).
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For pull-down, 1,500 ng of GFP-poly(A) RNA with 1 μL of RNaseIn in 1x STE buffer (5 μL
total) were heat denatured at 70 °C for 5 min. 10 molar eq. of 22/12/8 (GC)2 +(D-Arg)9 TIVA probe
(1-2 μL in STE) were added and the +light TIVA+RNA samples were placed under a
transilluminator for 7 min, mixed briefly, and then irradiated for an additional 7 min to ensure
complete photolysis. Both +light and -light tubes were incubated at 37 °C for 5 min, and then
placed on ice. To each ~7 μL TIVA+RNA sample, 0.6 μL 1 M spermidine and 150 μL of blocked
beads were added, and the mixtures were rotated for 40-60 min at 18 °C. After binding, the tubes
were placed on a magnetic stand for 3 min, and the supernatant was subsequently discarded.
Bead pellets were washed three times with 200 μL of ice-cold 1x BW buffer to remove unbound
material. During these washes, the bead pellets were gently rinsed while bound to the magnetic
stand but the pellets were not fully re-solubilized, allowing only 30 s to lightly settle after each
wash. Finally, the beads were resuspended in 120 uL of nuclease-free water with 1 μL of
RnaseIn, and captured mRNA was released by incubating at 70 °C for 5 min. Heated tubes were
immediately transferred to the magnetic stand and allowed to settle for 2 min, and 118 μL of the
eluent was collected to avoid transferring any beads left at the bottom of the tube. To further
eliminate any residual beads, the 118 μL eluent tubes were placed back onto the magnetic stand,
and after 2 min an 116 μL aliquot was transferred to fresh Lobind tubes. 5 μL of 100 mM NaCl /
75 mM Tris buffer was added, and the solutions were concentrated to 10 μL. 1 μL of this solution
was loaded onto a Bioanalyzer Nanochip, and the electrophoresis was performed according to
manufacturer’s instructions.

Fibroblast culture, lysis prep, pull-down, and detection
CCD-1112Sk human neonatal foreskin-derived fibroblasts (ATCC, Manassas, VA) were
cultured in IMDM with 10% FBS and penicillin/streptomycin in a 37 °C incubator with 5% CO2. For
pull-down experiments fibroblasts were seeded into wells of a 24-well plate and grown to
confluency overnight. On the day of the pull-down experiment the wells were gently washed twice
with 400 μL of PBS buffer, and then incubated with 250 μL of 0.5% trypsin at 37 °C for 5 min. 750
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μL IMDM media with 10% FBS were added to quench the trypsinization, and the cell mixtures
were transferred to individual sterile Lobind 1.5 mL tubes. Cell mixtures were centrifuged at
15,000 g for 5 min and washed with 200 PBS, then 5 μL RNaseIn were added followed by 50 μL
of ice cold 5x First-Strand buffer (250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2). To aid
in lysis, tubes were snap-frozen in liquid nitrogen and then thawed, and this freeze-thaw cycle
was performed twice. Fibroblast lysate tubes were set aside on ice.
Aliquots of 200 pmol of 22/12/8 (GC)2 +(D-Arg)9 TIVA in 50 μL PBS were incubated at 37
°C, while +light samples were irradiated for 5 min under a 410 nm LED. TIVA aliquots were
combined with lysate aliquots, and 50 μL blocked beads and 100 μL of 1x BW buffer were added
to each tube, and the mixtures were rotated at 18 °C for 40-60 min. Tubes were then washed
three times with ice-cold 1x BW buffer as described earlier, before being resuspended in 25 μL of
nuclease-free water for elution at 70 °C for 5 min. The eluent was returned to the magnetic stand
and 23 μL captured in fresh Lobind tubes. The concentration of RNA in these tubes was later
assessed on a Qubit 2.0 fluorescence detector according to manufacturer instructions.

Results
Stabilizing effects of (D-Arg)9
Before tweaking design of the core TIVA construct, we investigated the stabilizing effect
of the cationic, cell-penetrating peptide, (D-Arg)9, on pre-photolysis thermal stability (Figure 4.13).
The role of the pendant CPP is important to understand as there are alternate methods for
intracellular delivery of the TIVA probe, including ionically associated carrier peptides (Andaloussi
et al., 2011) or electroporation. The PS-22/9/9 probe from Chapter 3 had particularly low thermal
stability and poor caging, likely due in part to the lack of CPP. We found that the pendant CPP
exerts a stabilizing effect that is most dramatic in low-salt (10 mM NaCl) solution, raising the Tm of
the 18/7/7 and 22/9/9 probes by nearly 20 °C. In high-salt (100 mM NaCl) solution, the Tm was
raised by ∼5 °C, roughly equivalent to extending the duplex by four nucleotides. While the
disulfide-linked CPP is not expected to stay attached to the TIVA probe within the reducing
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environment of the cell, it should remain attached in the extracellular milieu where the probe is
challenged by serum nucleases.

Improved caging with 22/9/9 GC +(D-Arg)9 TIVA
To better align the duplex and reduce terminal fraying we first designed a new probe with
a terminal GC pair, “22/9/9 GC” (Figure 4.2). 22/9/9 GC TIVA probe was synthesized by
solid-phase phosphoramidite chemistry on ABI 394 synthesizer. Afterwards, the oligo was
cleaved from support by reaction with concentrated ammonium hydroxide for 17 h, with the
terminal DMT protecting group left on. The cleaved product was then purified by RP-HPLC on a
C18 column, and a representative HPLC trace is shown in Figure 4.4. To prepare for the (D-Arg)9
CPP conjugation, the oligo 5′ disulfide-linked alkyl-DMT group was removed by reduction in 500
mM TCEP for 1 h followed by separation and desalting through a Nap-10 column. The oligo –
with a free 5′ thiol – was then reacted with 6–8 equivalents of Cys(Npys)-(D-Arg)9 in a 1:1
formamide:water solution for 24–36 h. The resulting 22/9/9 GC +(D-Arg)9 oligo was subsequently
purified by AX-HPLC on Resource Q column (Figure 4.5) and buffer-exchanged into 1× STE
using Amicon 10k MWCO spin filters, concentrated to 100 μM, and stored at −20 °C.

22/9/9 GC +(D-Arg)9 characterization
The product was characterized by ESI-MS (Novatia), which confirmed the expected mass
for the 17,592 Da oligo-peptide conjugate (Figure 4.9a). The purity of the product was estimated
to be roughly 90% by RP-HPLC (Figure 4.9b), with the main impurities corresponding to product
with 1–2 cyanoethyl protecting groups remaining. These impurities resolve by HPLC very near to
the product, but are not anticipated to significantly affect the performance of the probe. Lastly, we
measured the melting temperature of the probe and found the GC pair to raise the pre-photolysis
Tm to 66 °C (Figure 4.9c, compare with Table 1 data). The mRNA target-bound Tm was roughly 53
°C, which is in close agreement with native 22/9/9 TIVA probe.
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We next assessed the FRET signal for both 18/7/7 +(D-Arg)9 and 22/9/9 GC +(D-Arg)9
probes at 1 μM in 1× STE, as dependent upon photolysis (“±hν”) and/or one equivalent of a
30mer 2′OMe polyA model target strand (“±polyA”) (Figure 4.14). We observed slightly decreased
starting FRET for the 22/9/9 GC TIVA probe (82%) relative to the original TIVA probe (87%),
perhaps due to the GC pair enforcing a somewhat different probe conformation that affects
relative positioning of the Cy3–Cy5 FRET pair. Because the construct has higher thermal stability
than similar probes without the GC pair, we reasoned that the somewhat lower FRET efficiency
may be caused by sequence-specific alterations to the stacking, isomerization, and subsequent
fluorescence of the terminal dyes (Kretschy et al., 2016) (Figure 4.14, column 1). Crucially, FRET
efficiency is improved for unphotolyzed 22/9/9 GC TIVA probe in the presence of polyA RNA by
13% relative to 18/7/7 TIVA probe (Figure 4.14, column 2). Furthermore, the net loss of FRET
after the addition of polyA RNA relative to its starting FRET has been reduced from 36.3% to
17.5%. This improvement increases confidence in the TIVA probe caging fidelity, particularly in
applications that require subcellular activation or lysis of one target cell in a larger pool of
unactivated cells. This more robust caging may have the side effect of marginally reducing
post-photolysis dissociation of the polyA blocking strands until they are actively displaced by
target mRNA (Figure 4.14, column 3). However, both probes reach 6% FRET upon
photoactivation in the presence of 30mer polyA RNA, so the terminal GC pair does not appear to
inhibit overall activation or target binding (Figure 4.14, column 4). We believe that the trends
observed were driven primarily by the addition of the GC pair, as we observed no significant
difference in FRET efficiency between 18/7/7 and 22/9/9 probes lacking a GC pair (Figure 4.15).

22/12/8 (GC)2 +(D-Arg)9 design
Although the poly(A)-induced loss of FRET was successfully reduced from -36.3% to
-17.5%, we wished to eliminate loss of FRET altogether. To improve the probe duplex alignment
and stability an additional terminal GC pair was added, for a total of two terminal GC pairs. This
inclusion raised the predicted melting temperature of the GC 5ʹ blocking strand enough that we
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initially redistributed an adenosine from the 5ʹ blocking strand (9xA → 8xA) to the 3ʹ blocking
strand (9xA → 10xA) to maintain facile post-photolysis strand dissociation. To further improve the
3ʹ blocking strand’s coverage of the capture strand we then added an additional two adenosines
(10xA → 12xA). Finally, we introduced a short (PEG)3 spacer into the hairpin turn. Simple
modeling experiments indicated that the photocleavable linker alone (~16 Å) was not long enough
to create a natural hairpin turn (25-30 Å) (Kim et al., 2006). This tension likely pulled nearby
bases into the turn, straining the alignment of the duplex and leaving any bases in the turn
exposed as potential toeholds for binding. By introducing this PEG spacer we intended to extend
the turn to a more natural 30-32 Å. With the relaxed hairpin turn and a blocking strand that is
longer and better aligned to the capture strand we anticipated a significant improvement in caging
stability. The resulting probe was named “22/12/8 (GC)2 +(D-Arg)9” (Figure 4.3).

22/12/8 (GC)2 +(D-Arg)9 synthesis and characterization
22/12/8 (GC)2 TIVA synthesis was performed on ABI 394 using standard solid-phase
phosphoramidite chemistry as described earlier for the 22/9/9 GC probe. 22/12/8 (GC)2 TIVA
+(D-Arg)9 identity was validated by ESI-MS (Figure 4.10a), which verified an expected principal
mass of 16,168.8 Da with an observed mass of 19,168.2 Da. +31.2 Da, +59.7 Da, +167.8 Da,
and +195.5 Da adducts were also identified, likely corresponding to combinations of sodium,
acetate, and HFIPA ions retained from the purification or electrospray preparation process. Based
upon the ESI-MS results and PAGE separation we estimate the product purity to be roughly 94%.
The remaining species contained one extra adenosine in the blocking strand or one missing
uridine in the capture strand. These single deletions or additions are common in oligonucleotides
synthesized with long repeating bases and are especially challenging to separate by HPLC.
Fortunately, these species are not expected to significantly affect TIVA functionality. The
remaining ~1% are truncation mutants which failed to deblock prior to Cy5 conjugation. Because
these probes lack cell-penetrating peptides, they are not anticipated to enter the cell and
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subsequently are not expected to pull down cellular mRNA or otherwise affect downstream
results.
Next, the thermal stability of the probe was characterized (Figure 4.10b). As expected,
the terminal 2xGC pair raised the pre-photolysis Tm by ~5 degrees relative to first-gen TIVA (64
°C) and ~3 degrees relative to a similar probe with only terminal GC pair (66 °C)(“22/9/9 GC
+(D-Arg)9”). The additional GC pair did not affect the post-photolysis, target-bound Tm, at 53 °C.

Assessing cagedness
To assess cagedness we first measured the Cy3-Cy5 FRET efficiency of the probe preand post-photolysis (± hν) and in the absence or presence of 1 eq of 30mer poly(A) model target
RNA (± poly(A)) (Figure 4.16). Adding the second GC pair further reduced pre-photolysis FRET of
the new probe to 72% (Figure 4.16, group 1), which we attributed to poorer fluorophore alignment
as a result of a duplex conformation enforced by the GC pair. For the first time we observed no
statistically significant change in FRET for 22/12/8 (GC)2 TIVA once 1 eq of poly(A) was added
(72.2 ± 2.6% -poly(A) → 73.6 ± 1.7% +poly(A)). As a result of this duplex stabilization the probe
was more dependent on having polyA RNA present to actively displace the blocking strand, as
evidenced by the relatively high post-photolysis FRET (44%) before poly(A) RNA was added.
With first-generation TIVA probe, a large decrease in FRET signal after activation reported mostly
upon the photoactivation itself. With this newer probe a decrease in FRET may give some
indication that the probe is not only photolyzed, but has also bound to its mRNA target. Taken
together, these results represent improvements in TIVA probe caging stability as well as the ability
of the FRET pair to report on probe caging, uncaging, and target binding.
As a second method of examining TIVA probe interaction with polyA RNA, we assessed
first-gen TIVA and 22/12/8 (GC)2 TIVA probe co-migration with polyA RNA using native PAGE
(Figure 4.17). First-gen TIVA showed a smeared co-migration in the presence of poly(A) (Figure
4.16a, lane 2), shifting its pre-photolysis band closer to the post-photolysis position (Figure 4.17a,
lane 4). Conversely, 22/12/8 (GC)2 TIVA showed no change in band shape or migration in the
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presence of polyA RNA (Figure 4.17b, lane 2 vs. lane 1). A faint Cy3 shadow can be observed on
the leading edge of the pre-photolysis bands for both probes, which is likely caused by the
cationic (D-Arg)9 peptide retarding the electrophoretic migration of the probe’s Cy5-containing
blocking strands.
Although FRET measurement and gel migration are helpful proxies for estimating the
TIVA probe caging efficacy, it remains useful to measure how much background RNA TIVA
carries through a pull-down experiment. Notably, fraying or misalignment of the duplex terminus
could theoretically perturb FRET signal without impacting caging, and the hybridization strength
necessary for co-migration on a gel may not reflect the hybridization strength needed for mRNA
to remain annealed to the TIVA-Biotin:Streptavidin bead complex throughout the repeated
washes of the pull-down procedure. Therefore, as an additional in vitro control we performed a
pulldown assay using a poly-adenylated GFP transcript as a model mRNA target (~1,200 nt,
Figure 4.18a). This experiment was performed on a sufficiently large scale to allow direct analysis
of any isolated mRNA by nano-chip capillary electrophoresis without the need for amplification. In
this way we sought to measure background signal caused by probe uncaging, without additional
sources of background signal introduced by amplification. Gratifyingly, we found that 22/12/8
(GC)2 TIVA did not pull down a significant amount mRNA prior to photolysis (Figure 4.18b), but
did pull down mRNA matching the target length after photolysis (Figure 4.18c). This result
corroborates the FRET and PAGE results, giving confidence that PAGE could be used in future
experiments to assess caging quickly and inexpensively without need for the longer RNA
pull-down procedure.
Finally, to ensure that the results observed with the synthetic GFP-poly(A) transcript were
not sequence-specific, we performed another pull-down assessment of 22/12/8 (GC)2 TIVA using
cell lysate. In brief, human fibroblast cells were grown to confluency in 2 cm2 wells and then
trypsinized, combined with an RNase inhibitor cocktail, and lysed by high-salt buffer combined
with two liquid nitrogen freeze-thaw cycles. Fresh lysate was then added to aliquots of photolyzed
or unphotolyzed 22/12/8 (GC)2 TIVA probe and incubated at 37 °C for 15 min. Afterwards the
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TIVA-bound lysate was incubated with streptavidin beads, unbound material was washed away
repeatedly with ice cold BW buffer, and any captured mRNA was subsequently eluted off the
beads. Because we were no longer looking for the signature length of an individual transcript, we
instead measured the elution’s bulk mRNA concentration using a Qubit 2.0 fluorimeter (Figure
4.19). We observed a ~12-fold reduction of signal without photolysis, solidifying our impression of
22/12/8 (GC)2 as having finally achieved sufficiently robust caging for cellular and potentially even
sub-cellular experiments.

Conclusions
In this work we have investigated the caging of first-generation TIVA probe and, finding it
lacking, we sought to improve it with a variety of rational modifications. A longer duplex and
(D-Arg)9 CPP were identified as important contributors to thermal stability, at all salt conditions
tested (10–100 mM NaCl). To reduce hairpin fraying we first introduced a terminal GC pair to
align the duplex with a specific interaction. This addition had the effect of marginally diminishing
TIVA FRET efficiency alone in buffer, but critically reduced fraying in the presence of poly(A) RNA
by more than half. To eliminate the remaining poly(A)-induced loss of FRET we engineered an
additional terminal GC pair, incorporated a (PEG)3 spacer to relax the hairpin turn, and modified
the lengths of the 3′ and 5′ blocking strands. Afterwards, no significant interaction was observed
between unphotolyzed TIVA and 30mer poly(A) RNA in native gel co-migration or FRET analysis,
and no significant pull-down was observed when incubated with GFP-poly(A) transcripts or
complete fibroblast lysate unless the probe was photoactivated. We expect that such robust TIVA
caging will improve the quality of all cellular TIVA experiments, in particular those that are
performed on subcellular regions of cells such as individual dendritic processes or in applications
where a significant number of unactivated cells have to be lysed along with the activated target
cell.
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Figure 4.1: FRET analysis of 18/7/7 +(D-Arg)9 TIVA probe in 1x STE buffer with or without

photoactivation (“+Light”, “-Light”) and with or without 1 eq. of a 30mer poly(A) RNA (“+Poly(A)”,
“-Poly(A)”).
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Figure 4.2: Structural scheme of 22/9/9 GC +(D-Arg)9 TIVA

98

Figure 4.3: Structural scheme of 22/12/8 (GC)2 +(D-Arg)9 TIVA
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Figure 4.4: RP-HPLC purification of crude 22/9/9 GC probe after solid-phase synthesis and cleavage.
Separation was performed on C-18 column under a gradient of increasing acetonitrile in 0.5 M TEAA, with
the product eluting at roughly 28 min.
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Figure 4.5: AX-HPLC purification of 22/9/9 GC probe after conjugation to (D-Arg)9 cell-penetrating peptide.
Separation was performed on Source 15q ion-exchange column under a gradient of increasing NaClO4 in
1:1 formamide:Tris-HCl buffer, with the product eluting at roughly 24 min.
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Figure 4.6: RP-HPLC purification of crude 22/12/8 (GC)2 TIVA probe after solid-phase synthesis.
Separation was performed on C-18 column under a gradient of increasing acetonitrile in 0.5 M TEAA, with
the product eluting at roughly 28 min.
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Figure 4.7: AX-HPLC purification of (D-Arg)9-conjugated 22/12/8 (GC)2 TIVA probe. Separation was
performed on Source 15Q ion-exchange column under a gradient of increasing NaClO4 in 1:1
formamide:Tris-HCl buffer, with the product eluting at roughly 26 min.
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Figure 4.8: ESI-MS analysis of 22/9/9 +(D-Arg)9 TIVA. ESI-MS verified the product mass (16,913 Da
predicted, 16,912 Da observed). The main impurity corresponded to TIVA product with one missing 2´F-U
(-307 Da), which is not expected to significantly impact probe performance.
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Figure 4.9: (A) ESI-MS of 22/9/9 GC +(D-Arg)9 product. 17,592 Da expected, 17,592 Da observed. (B)
Re-injection of purified 22/9/9 GC TIVA probe on RP-HPLC. (C) Melting curve analysis of 22/9/9 GC while
caged (red), photolyzed (blue), or photolyzed and target-bound (green).
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Figure 4.10: (A) ESI-MS of 22/12/8 (GC)2 TIVA +(D-Arg)9 probe. 19,168.8 Da calculated, 19,168.2 Da
observed. (B) Thermal melt analysis of 22/12/8 (GC)2 TIVA +(D-Arg)9 probe caged (red), photolyzed (blue),
and photolyzed while bound to poly(A) RNA 30mer (green).
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Figure 4.11: Native agarose gel separation of linearized GFP transcripts before (lane 2) and after (lane 3)
polyadenylation. 50 pmol of each oligo was loaded into a 15% polyacrylamide gel and run for 2 h on ice at
100 V.
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Figure 4.12: Nanochip capillary electrophoretic separation of GFP-poly(A) RNA, verifying expected 1.2-1.4
kb length.
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Figure 4.13: Melting temperatures of 18/7/7 and 22/9/9 TIVA probes with or without (D-Arg)9 cell-penetrating
peptide in 10, 50, or 100 mM NaCl solution. Shown are averages and ranges of two forward and reverse
melts for each sample.
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Figure 4.14: Cy3-Cy5 FRET efficiency of 1 µM 22/9/9 GC +(D-Arg)9 TIVA probe compared to 18/7/7
+(D-Arg)9 TIVA probe in 1x STE buffer with or without 1 eq of 30mer poly(A) target and/or photolysis.
Average and standard deviation shown for three or more samples under each condition.
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Figure 4.15: FRET efficiencies of 18/7/7 and 22/9/9 TIVA probes in buffer, pre-photolysis. FRET efficiencies
were measured for both probes at 1.0 µM in 1x STE buffer.
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Figure 4.16: Cy3-Cy5 FRET efficiency comparison of three TIVA probes, with or without photolysis (± hν)
and with or without 1 eq of 30mer 2′-OMe polyA RNA (± polyA). Average and standard deviation shown for
three or more samples under each condition.
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Figure 4.17: Native PAGE analysis of (A) 18/7/7 +(D-Arg)9 and (B) 22/12/8 (GC)2 TIVA +(D-Arg)9. Cy3
(green) and Cy5 (red) direct excitation are imaged.
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Figure 4.18: Nanochip capillary electropherogram traces of GFP-poly(A) transcript. Direct electrophoresis of
GFP input transcript (~1,200 NT). (B) Pre-photolysis pull-down of GFP transcript by 22/12/8 (GC)2 TIVA
probe. (C) Post-photolysis pull-down of GFP transcript by 22/12/8 (GC)2 TIVA probe.
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Figure 4.19: Comparison of RNA pulled down by 22/12/8 (GC)2 +(D-Arg)9 TIVA from human fibroblast lysate
without (-hv) and with (+hv) photoactivation. Error bars show standard deviation of 3 or more replicates.
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Chapter Five
Ru-TIVA: a circularly-caged probe activatable by 2-P, near-IR light
In collaboration with Teresa Rapp & Jaehee Lee
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Introduction
The quest to apply caged oligonucleotides to deeper regions of tissue is ultimately
hamstrung by the near-UV activation of o-nitrobenzyl and other organic caging groups: light with
wavelengths shorter than 650 nm can only penetrate, at most, 1 cm deep into tissue due to
absorption and scattering effects of water, hemoglobin, and oxy-hemoglobin (Weissleder, 2001).
Selection of smaller, more accessible model systems such as chick or zebrafish embryos allows 1
cm of light penetration to reach more of the overall organism, but applications in larger model
organisms and clinical usage in human patients necessitate photoactivation in the 700-900 nm
region, which has been shown to penetrate up to ~3 cm (Henderson and Morries, 2015; Hudson
et al., 2013). Moving towards near-IR light also reduces the risk for UV-induced toxicity effects
such as cross-linking reactions by DNA and proteins (Pattison and Davies, 2006). Furthermore,
2-photon excitation

in the 700-800 nm region is especially attractive, as it reduces

photoactivation of probe outside of the focal plane, yielding significantly finer depth control (Denk
et al., 1990).
Inorganic ruthenium polypyridyl complexes have an extensive history as photolabile
protecting groups (Li et al., 2018), recently utilized by the Etchenique lab to cage dopamine for
2-P, IR-mediated release in brain tissue (Araya et al., 2013) and the Turro lab for selective
release of imatinib, an anticancer drug, within a tumor (Rohrabaugh et al., 2018). In 2015, our lab
introduced RuBEP (Ru(bipyridine)2(3-ethynylpyridine)2), a photocleavable, homobifunctional linker
capable of coupling two azide-containing compounds together via Cu(I)-mediated azide-alkyne
cycloaddition (CuAAC, or “bis-click reaction”) with the two alkyne groups on its monodentate
ligands (Griepenburg et al., 2015). Upon excitation with 450 nm 1-P light or 700-900 nm 2-P light,
Ru(II) exchanges one of its two monodentate ligands with solvent, releasing its linkage (Figure
5.1). In an initial proof-of-concept, RuBEP was used to link the 3′ and 5′ terminal azides of an
antisense morpholino targeting chordin in zebrafish embryos. While RuBEP was engaged, the
morpholino remained cyclically constrained, unable to bind to its target. Once activated with 1-P
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450 nm light, 92% of embryos developed the chordin phenotype. As an additional control,
unbound RuBEP was injected into embryos and was photoactivated without apparent toxicity or
phenotypic response.
In this work, we take the RuBEP-linked circular oligo design used to cage morpholinos
and seek to adapt it to cage TIVA oligonucleotide probes. In addition to the listed benefits
afforded by 2-P near-IR activation, circular caging also eliminates the need for a complementary
blocking strand. In theory, photolysis and linearization of a circular “Ru-TIVA” could be faster than
activation of both nitrobenzyl groups and subsequent dissociation of the blocking strands in a
hairpin TIVA, while also eliminating any risk for off-target effects from the dissociated blocking
strands. However, as discussed in the previous chapter, maintaining the lowest possible
pre-photolysis background pull-down is an important criteria for the design of TIVA probes. In the
phenotypic assays used to gauge background activity of previous circular probes, relatively low
levels of background activity may be masked by a lack of phenotypic response, but in
transcriptomic applications all background signal is keenly observed due to amplification cycles
prior to sequencing. The need for robust caging, sufficiently long capture strands for high
capture-affinity, spectral separation between imaging and RuBEP activation, and effective
synthesis and purification have imposed a number of challenging constraints upon the design of
Ru-TIVA. As a result, we present here three incrementally improved Ru-TIVA probes, Ru-TIVA v1
(Figure 5.2), Ru-TIVA v2 (Figure 5.3), and Ru-TIVA v3 (Figure 5.4), and discuss the rational
design process that guided each progression. Finally, we demonstrate the potential for circular
Ru-TIVA to be activated by 2-P 713 nm light within hippocampal tissue slices, and discuss the
challenges facing probe synthesis and caging.

Experimental methods
General synthesis of Ru-TIVA probes
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Ru-TIVA solid-phase syntheses were performed at 1 μmol scale on an ABI 394
synthesizer as described previously in Chapters 2 and 3, with phosphoramidite and coupling
reagents supplied by Glen Research. RuBEP was synthesized and characterized as described
previously (Griepenburg et al., 2015). All RP-HPLC (Agilent 1100S) purifications were performed
on a C18 column with a flow rate of 1.0 mL min−1 and a gradient of increasing acetonitrile (B) in
0.1 M TEAA (A).

Synthesis of Ru-TIVA v1
After solid-phase synthesis and cleavage, linear bis-amino Ru-TIVA v1 was RP-HPLC
purified utilizing the hydrophobicity of the 5′ DMS(O)MT protecting group in a gradient of 20% B at
0 min, 60% B at 46 min, 20% B at 50 min. The product eluted at 34 min with a yield of 90-120
nmol. The terminal DMS(O)MT protecting group was subsequently removed by treatment with
20% acetic acid for 1 h, after which the acetic acid was removed by vacufuge and the
deprotected oligo was desalted through a Nap-5 column. To convert the linear bis-amino probe to
the linear bis-azido version, purified bis-amino probe (400 uM) was reacted with 20 eq of
azidobutyrate NHS ester (Glen Research) for 2 h at rt in 0.1 M bicarbonate buffer (pH 9), and
excess NHS ester was removed by desalting through a Nap-5 column. Azide labeling was nearly
quantitative, and was verified by RP-HPLC on a C18 column in a gradient of 20% B at 0 min,
60% B at 46 min, 20% B at 50 min. The clean bis-azide product eluted at ~29 min. The
circularizing bis-blick reaction was performed at a 5.0 nmol scale, using 0.83 eq of RuBEP, 10 eq
of copper sulfate, 100 eq of THPTA ligand, 400 eq of sodium ascorbate, at a final Tris-HCl buffer
(pH 7.5) concentration of 20 mM and overall reaction volume of 20 mM. The click reaction
proceeded for 1 h at rt and other than brief initial vortexing did not require mixing. Successfully
circularized probes were separated from failed probes (multiple oligos per RuBEP or vice versa)
and Cu-degraded material using RP-HPLC with a gradient of 20% B at 0 min, 60% B at 46 min,
20% B at 50 min. Circular Ru-TIVA v1 was collected at ~23 min, with a post-click recovery of
32-35%. Recovered circular Ru-TIVA v1 was dried down to remove ACN, and then
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buffer-exchanged into nuclease-free water using a 10k MWCO spin-filter. Finished Ru-TIVA v1
was stored in a black opaque box at -20 °C.

Synthesis of Ru-TIVA v2
Linear bis-amino Ru-TIVA v2 was synthesized without the hydrophobic DMS(O)MT group
to aid purification, so the RP-HPLC collection gradient was expanded to aid in separation: 35% at
0 min, 45% at 42 min, 35% at 45 min, with linear bis-amino Ru-TIVA v2 eluting at ~19 min and a
yield of 60-90 nmol. Collected linear bis-amino Ru-TIVA v2 was labeled with azidobutyrate NHS
ester as described for Ru-TIVA v1, and the purity of the linear bis-azido Ru-TIVA v2 was
assessed by RP-HPLC: 20% B at 0 min, 60% B at 46 min, 20% B at 50 min, with the labeled
bis-azido oligo running cleanly at ~37 min. To circularize the oligo, a bis-click reaction was
performed at 5.0 nmol scale with 1.3 eq RuBEP linker, 10 eq copper sulfate, 12 eq TCEP, 5%
ACN by volume, and in sodium bicarbonate buffer (pH 7.5) at a final buffer concentration of 10
mM and final solution volume of 125 μL. The reaction was briefly vortexed and then allowed to
proceed for 1 h at rt. Circular product was separated by RP-HPLC on a C18 column in a gradient
of 32% B at 0 min, 46% B at 46 min, 90% B at 50 min, 90% B at 55 min, and 32% B at 60 min.
The product eluted at ~23 min, at a post-click recovery of 14-19%. The product was
buffer-exchanged and stored as described for Ru-TIVA v1.

Synthesis of Ru-TIVA v3
Following solid-phase synthesis and cleavage, deprotected linear bis-amino Ru-TIVA v3
was purified by RP-HPLC in a gradient of 32% B at 0 min, 46% B at 46 min, 90% B at 50 min,
90% B at 55 min, and 32% B at 60 min. The product eluted at ~19 min at a yield of 70-100 nmol.
Linear bis-amino Ru-TIVA v3 was azide labeled with azidoacetic acid NHS ester (Sigma Aldrich)
instead of azidobutyrate NHS ester to keep chain lengths from RuBEP to the oligo core as short
as possible. NHS ester labeling conditions were as described for Ru-TIVA v1 & v2, although the
excess of azidoacetic acid NHS ester was increased from 20 eq to 200 eq. Linear bis-azido
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Ru-TIVA v3 was assessed by RP-HPLC after labeling using a gradient of 32% at 0 min, 40% at
32 min, 90% at 38 min, 90% at 46 min, and 32% at 50 min, with the completely labeled peak
observed at 30 min. Linear bis-amino Ru-TIVA v3 was circularized at a 5 nmol scale, with 10 eq
copper sulfate, 12 eq of TCEP, 6% ACN by volume, in sodium bicarbonate (pH 7.5) buffer at a
final concentration of 10 mM and final reaction volume of 125 uL. 0.75 eq of RuBEP was added
initially, and an additional 0.75 eq RuBEP was added at 1h and 2h, with the reaction allowed to
proceed for 3h total at rt. The clicked Ru-TIVA v3 was separated by RP-HPLC on a gradient of
32% B at 0 min, 40% B at 32 min, 90% B at 38 min, 90% B at 46 min, and 32% B at 50 min. The
circular product eluted closely with impurities corresponding to probes with partially capped
aminies and/or mismatched TIVA:RuBEP stoichiometry. The right half of the ~27 minute peak
shoulder ‒ corresponding to the circular product ‒ was captured at a yield of 5-9%. The isolated
probe was buffer exchanged into 1x STE buffer and stored at -20 °C.

Mass determination
Ru-TIVA v1 was synthesized prior to adoption of ESI-MS and did not fly on MALDI-MS,
so no mass characterization was obtained. Ru-TIVA v2 and Ru-TIVA v3 masses were determined
by Novatia, LLC using a LC-MS system with electrospray injection (Oligo HTCS). Ru-TIVA v2 was
observed as a principal peak with a mass of 12,036.5 Da (calculated 12,040.5 Da). A +19 Da
adduct was observed at 14% relative intensity, likely corresponding to photolyzed Ru-TIVA v2
(+18 Da), as well as an unknown -68 Da peak at 11% relative intensity. Ru-TIVA v3 was observed
with a principal mass of 11,444.6 Da (calculated 11,442.6 Da). A +18 Da adduct was observed at
6.5% relative intensity, also likely corresponding to photolyzed Ru-TIVA v3, and a -308 Da peak
(1.2% relative intensity) was identified as a functionally-similar -U deletion mutant version of the
circular probe.
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FRET sample preparation and measurement
60 μL TIVA probe samples were prepared at 1.0 μM in 1× STE buffer: two samples mixed
with one equivalent of 30mer polyA 2′-OMe RNA as a model polyA tail (“+polyA”) and two
samples without polyA RNA (“−polyA”). One −polyA and one +polyA sample were then
photoactivated (“+hν”), while the remaining two samples were left unactivated (“−hν”).
Photoactivation of Ru-TIVA v1 was performed using a TL-355R Ultraviolet Transilluminator
(Spectroline, Westbury, NY), irradiating the samples at 365 nm, 9 mW cm−2 for 8 min, followed
by brief mixing, and then irradiating for an additional 8 min. Photoactivation of Ru-TIVA v2 and v3
was performed using a 450 nm LED with plastic collimator connected to a variable power source.
Samples were irradiated for 5 min without mixing. Cy3–Cy5 FRET emission was measured on a
Cary Eclipse fluorimeter (Varian) with Cary Temperature Controller (Agilent) set to 20 °C. Cy3
was excited at 552 nm and the emission spectrum was collected from 555–705 nm. FRET
efficiency was approximated using the formula FRET = Ia/(Ia + (Id × γ)), where Ia is the emission
intensity of the FRET acceptor at 665 nm, Id is the emission intensity of the FRET donor at 565
nm, and γ is a correction factor of 2.0 for the two fluorophores’ differing quantum yields. For
Cy5-Cy5.5 measurement Cy5 was excited at 645 nm and the emission spectrum was collected
from 655-755 nm. Ia was the intensity of the FRET acceptor at 692 nm, and Id was the intensity of
the FRET donor at 667 nm. We chose to utilize this approximation method over more complex
photobleaching or single-fluorophore probe methods as it can also be used to estimate the FRET
signal from TIVA probe in real-time microscopy applications.

Hippocampal study
Coronal brain slices (220-270 mm) were prepared C57BL/6 mice with a vibratome and
subsequently loaded with Ru-TIVA-tag (6 mm) for 90 min at room temperature (RT). Imaging and
photolysis were performed in the hippocampus using the 730 nm lasers for uncaging at 15%
power on previously described instrumentation (Lovatt, D. et al, 2014). Loading was confirmed by
detecting Cy5.5 signal in the emission range excited by 633 nm, and uncaging was performed
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using the 730 nm laser while recording FRET excited by 633 nm and simultaneous capturing in
Cy5 (640 - 675nm) and Cy5.5 (680-704nm) emission ranges.

Results
Ru-TIVA v1
As a starting place for the design of Ru-TIVA, we selected an 18mer poly(U) capture
strand, which had been sufficiently long to capture mRNA in our previous hairpin designs. The
invaluable Cy3 and Cy5 FRET reporter pair were placed at opposite ends of the capture strand,
and an internal biotin phosphoramidite was chosen to keep the 3′ and 5′ termini clear for clicking
to the RuBEP linker. To add azides to our probe we employed terminal amino modifier
phosphoramidites, which would be converted to azides with an azidobutyrate NHS ester after
solid-phase synthesis.
Linear, bis-amino Ru-TIVA v1 was initially synthesized on an ABI 394 synthesizer using
solid-phase,

phosphoramidite

chemistry.

To

reduce

capping

of

amino

modifiers

by

backbone-released cyanoethyl groups during ammonia-mediated deprotection, an initial
cyanoethyl deprotection was added prior to cleavage: 10 mL of 10% DEA was slowly pushed
through the support with a syringe over 2 min, followed by a 10 mL wash with ACN, and then the
column was dried with forced air. Afterwards the probe was cleaved from the support in 1.3 mL of
30% AmOH for 17-18 h at rt, and then the AmOH was removed in a vacufuge set to the most
volatile vapor point. The linear bis-amino Ru-TIVA v1 was subsequently purified from failed
sequences using Reverse Phase (RP)-HPLC on a C18 column in a gradient of 0.1 M TEAA in
increasing ACN (Figure 5.5), with the product isolated at ~37 min based upon the absorbance of
the oligo bases, Cy3, and Cy5. To convert the linear bis-amino probe to the linear bis-azido
version, purified bis-amino probe (400 uM) was reacted with 20 eq of azidobutyrate NHS ester for
2 h at rt in 0.1 M bicarbonate buffer (pH 9), and excess NHS ester was removed by desalting
through a Nap-5 sephadex column. Near-quantitative azide-labeling of the probe was verified by
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RP-HPLC (Figure 5.6). The circularization bis-click reaction was performed at a 5.0 nmol scale,
using 0.83 eq RuBEP, 10 eq copper sulfate4, 100 eq THPTA ligand, 400 eq sodium ascorbate, at
a final Tris-HCl buffer (pH 7.5) concentration of 20 mM and overall reaction volume of 20 mM.
The click reaction proceeded for 1 h at rt, and the successfully circularized probes were
separated from failed probes (multiple oligos per RuBEP or vice versa) and Cu-degraded material
using RP-HPLC on a C18 column in a gradient of 0.1 M TEAA in increasing ACN (Figure 5.7).
Circular Ru-TIVA was collected at ~23 min, with a post-click recovery of 32-35%.
In addition to the shift in RP-HPLC retention, circularization was verified by Cy3-Cy5
FRET analysis (Figure 5.8): 1 μM Ru-TIVA probe in 1x STE buffer exhibted 90% FRET efficiency.
Upon photolysis under a 365 nm Transilluminator for 2 min the FRET efficiency dropped to 38%,
and addition of 1 eq of 30mer poly(A) RNA as a loose model for a mRNA poly(A) tail further
decreased the FRET signal to 23%. As additional characterization of mRNA binding, a 20%
polyacrylamide native gel-shift assay was performed on circular Ru-TIVA v1 in comparison to
linear bis-azido Ru-TIVA v1, with/without photoactivation and with/without 30mer poly(A) RNA
(Figure 5.9). Significantly faster electrophoresis was observed for circularized Ru-TIVA v1 (lane 2)
compared to linear bis-azido Ru-TIVA v1 (lane 1). When poly(A) RNA is added to unphotolyzed
circular Ru-TIVA v1 it significantly retards electrophoresis, indicating some degree of association
between the two strands (lane 3). Photolyzed Ru-TIVA v1 splits into two bands (lane 4), possibly
due to minor differences in secondary structure caused by random release of RuBEP from either
the 3′ or 5′ ends of the probe. Both linear photolyzed Ru-TIVA v1 bands are observed to shift
upwards in the presence of poly(A) RNA (lane 5) to a migration point similar to linear bis-azido
Ru-TIVA with poly(A) RNA (lane 6), suggesting that photolyzed Ru-TIVA v1 binds to its target.
Overall, these results generated confidence that Ru-TIVA v1 was successfully circularized and
could bind to target mRNA after photolysis. However, the heavily altered migration of circular
Ru-TIVA v1 in the presence of mRNA cast doubt upon the effectiveness of its caging.
Nevertheless, aliquots of purified Ru-TIVA v1 were delivered to the Eberwine lab for
biological assessment in neurons. Before the caging and activation of Ru-TIVA v1 could be
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tested, however, we encountered issues with inadvertent uncaging of RuBEP by the 543 nm
HeNe laser used for Cy3-Cy5 imaging, even at low laser powers. This was surprising due to the
extremely low absorbance of RuBEP at 543 nm, but ultimately the inability to safely image
Ru-TIVA v1 without uncaging it necessitated modifying the probe design with a new reporter pair.
The association of unphotolyzed circular Ru-TIVA with poly(A) RNA observed in the native gel
assay was also concerning, but at this time (2014) we weren’t yet as focused on caging and had
yet to develop the bench-top pull-down assays discussed in chapters 3 and 4.

Ru-TIVA v2
To address inadvertent RuBEP photolysis during Cy3 excitation, we initially attempted to
shift the reporter pair as far into the red as possible, selecting a Cy5.5-Blackberry quencher
(BBQ-650) pair. However, the 8-alkoxyjulolidine moiety at the heart of BBQ-650 proved too
delicate to achieve acceptable yields during solid-phase synthesis and cleavage (data not
shown), and this approach was eventually abandoned. Instead, we opted for a Cy5-Cy5.5
reporter pair. The larger Förster radius of the Cy5-Cy5.5 pair (73 Å) relative to the Cy3-Cy5 pair
(60 Å) (Hohng et al., 2004) combined with the way in which both fluorophores remained attached
to the capture strand after photolysis rather than dissociating away as in previous hairpin TIVA
designs necessitated further adjustments to the Ru-TIVA v2 probe to maintain a useful FRET
change. To further separate Cy5 and Cy5.5 after photolysis, a 5mer UUCUU:AAGAA stem was
introduced. This stem was also intended to act as a longer capture strand (18x U → 22x U) while
potentially templating the intramolecular bis-click cyclization with RuBEP (Figure 5.3).
Ru-TIVA v2 was synthesized as described for Ru-TIVA v1 with minor modifications. After
purification of the linear bis-amino Ru-TIVA v2 (Figure 5.10), the oligo was azide-modified (Figure
5.11). Circularization was performed at 5.0 nmol scale with 1.3 eq RuBEP linker, 10 eq copper
sulfate, 12 eq TCEP, 5% ACN by volume, and in sodium bicarbonate buffer (pH 7.5) at a final
buffer concentration of 10 mM and final solution volume of 125 μL. The product was separated by
RP-HPLC on a C18 column in a gradient of 0.1 M TEAA in ACN, with the product eluting at ~23
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min (Figure 5.12), at a post-click recovery of 17-19%. The identity of the circularized product was
confirmed by ESI-MS (12,040 Da calculated, 12,037 Da observed) (Figure 5.13a). The Cy5-Cy5.5
FRET efficiency was assessed with/without photolysis (“hv”) and with/without 1 eq 30mer poly(A)
RNA (“PolyA”) (Figure 5.13b). High FRET (81%) was observed for circular material, which
dropped to 36% after photolysis, suggesting that the probe was successfully circularized by the
bis-click reaction and could be linearized upon photolysis. Poly(A) RNA was not found to have a
significant effect on FRET, both before and after photolysis.
Purified Ru-TIVA v2 was applied by the Eberwine lab to mouse hippocampal tissue, with
delivery mediated by ionically-associated PepFect6 peptide (Figure 5.14). Ru-TIVA v2 was found
to broadly label cells in the tissue slice, with relatively even cytosolic signal. Excitingly, the probe
could be rapidly photoactivated by 2-P 713 nm light, and a subsequent decrease in FRET
intensity was observed. These results validated our initial enthusiasm, serving as the first
evidence of RuBEP being photoactivated in living tissue with 2-P light. Before biological trials
could progress further, however, we applied Ru-TIVA v2 to the GFP-poly(A) pull-down procedure
(performed as described in Chapter 4) to assess its caging. Perhaps unsurprisingly, given the
conserved 18mer loop between Ru-TIVA v1 and v2 as well as the added lability of the stem,
Ru-TIVA v2 was found to pull down unacceptable amounts of GFP-poly(A) transcripts prior to
photolysis (Figure 5.15). Additionally, photolyzed Ru-TIVA v2 demonstrated an unexpected
enrichment of 4+ kb fragments. Because the only oligos involved were the ~30mer Ru-TIVA v2
and the 1.2-1.4 kb GFP-poly(A) RNA, this seemed to indicate a concatenation effect mediated by
Ru-TIVA’s self-complementarity.
In retrospect, while we didn’t want the added stem to perturb probe-opening and
subsequent RNA binding after photolysis, a Tm of ~37 °C was far too low. The lability of this stem
in combination with the move of the RuBEP linkage from the circle itself to the base of the stem
likely increased the poly(A)-accessible region of the probe significantly and worsened the probe’s
caging further relative to Ru-TIVA v1. With this in mind, we turned towards a new design of
Ru-TIVA aimed at conclusively addressing any caging issues.
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Ru-TIVA v3
To reinforce the probe’s caging integrity we shifted bases from the open capture loop (18
→ 10 bases) into a longer stem (5 → 8 bases), adopting a design half-way between traditional
cyclic oligos and our previous hairpin designs (Figure 5.4). At the bottom of the stem we
introduced a GC:GC pair, which had been an important part of aligning the duplex and
subsequently reinforcing the caging of 22/12/8 (GC)2 +(D-Arg)9 TIVA. Finally, we moved the
RuBEP linkage site from the base of the stem up into the neck of the loop, where it was expected
to have a more impactful role in keeping the construct inaccessible prior to photolysis.
Synthesis of Ru-TIVA v3 proceeded as described for Ru-TIVA v2, including post-cleavage
crude purification (Figure 5.16) and azidoacetate NHS ester labeling (Figure 5.17). Cyclization
was performed in similar conditions, but RuBEP was added incrementally (0.75 eq per hour for 3
h) to drive the reaction to completion without promoting oversaturation of oligos by multiple
RuBEP. After the cyclizing bis-click reaction of bis-azido Ru-TIVA v3 with RuBEP, purification was
attempted by RP-HPLC on a C18 column using a gradient of 0.1 M TEAA in increasing ACN
(Figure 5.18). Despite high column temperatures (70 °C), the longer stem appeared to remain
intact during purification. Due to this strong secondary structure and the overall larger size of the
oligo, the successful intramolecular addition of RuBEP offered minimal separation from starting
material or other side-products, especially compared to separation of clicked Ru-TIVA v2, which
could be separated based upon large changes in secondary structure. Furthermore, although the
10% DEA treatment prior to CPG cleavage reduced the number of amines that were capped by
cyanoethyl groups, a small number of capped amines were able to disrupt the delicate
stoichiometric balance of the downstream intramolecular bis-click reaction: each capped amine
creates an oligo bound to only one of RuBEP’s 3-ethynylpyridine (3EP) ligands, leaving the other
3EP available to coordinate intermolecularly to another oligo, creating a chain of polymerization.
Even in bis-azido Ru-TIVA batches with minimal capping, side-products were still observed with
multiple oligos per RuBEP or multiple RuBEPs per oligo. Surprisingly, the product peak observed
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on the RP-HPLC could still be separated into two fractions, and despite their overlap the later
fraction showed predominantly product and minor adducts (90% rel. intensity) by ESI-MS (Figure
5.19). However, Ru-TIVA v3 was only recovered at 5-8% yield after click reaction. Limitations in
probe yield have hampered its subsequent characterization and application, so further
modifications to the probe design and synthesis / purification will need to be considered.

Conclusions
Based upon potential improvements to tissue penetration, depth-control, toxicity, and
activation kinetics, a Ru-TIVA probe that can be activated by 2-P, near-IR light remains an
exciting prospect. In this work we have demonstrated the ability to synthesize such circular
probes and activate them with 2-P near-IR light in living tissue. However, creating a probe that is
well caged, easily synthesized, and requires minimal purification remains challenging: (1) a
sweet-spot must be identified between a capture strand that is sufficiently long but not so long
that it opens the cyclic probe up to pre-photolysis background binding. One promising approach is
to use modified oligos such as LNA or PNA, which can create higher binding affinities from
shorter, more sterically constrained loops. (2) Stem lengths need to be long enough to separate
the reporter pair post-photolysis for a useful FRET change and also long enough to keep the
stem from opening in the presence of poly(A) RNA, but stems that are too long and stable
complicate post-click purification strategies such as RP-HPLC that exploit differences in
secondary structure pre- vs post-click. To further disrupt the secondary structure of un-clicked
probe it may be possible to better separate the click reaction products by a large-scale formamide
denaturing gel, extracting the product band. While this may improve the separation of
covalently-circularized product from denatured linear material, and thus improve recovery, overall
yields of gel extractions are typically significantly lower than RP-HPLC, so a net gain to recovery
is uncertain. If a stem is not needed for caging purposes, it could be eliminated entirely along with
the FRET reporter pair, as Ru-TIVA v1 demonstrated that a stem isn’t required for clicking. If an
activation reporter was required, it may be possible to synthesize a Cy5-RuBEP-Cy5.5 construct
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that could be intermixed with the Ru-TIVA and PF6 complex during cellular delivery. (3) Even with
an optimal probe design, achieving perfectly stoichiometric, intramolecular addition of RuBEP is
non-trivial. Previous RuBEP-oligo efforts were able to leverage the poor solubility of the product
relative to side-products as a means of facile purification ‒ a convenient strategy not applicable to
all RuBEP-caged probes. Relative to other cyclic oligos with one terminal amine, having a second
amine doubles the chances for capping ‒ currently considered a random and largely unavoidable
process during oligo deprotection ‒ and due to the homobifunctional nature of RuBEP, small
amounts of capping can significantly derail the click downstream click reactions. Identifying a way
to completely eliminate capping is clearly a priority, although no fail-proof procedure is currently
known. As a starting point, the duration and concentration of the cyanoethyl-removing DEA
treatment can be tested for further optimization.
An alternative strategy is to abandon the use of Ru(II) polypyridyl homobifunctional
linkers, instead incorporating a Ru(II) polypyridyl complex into a phosphoramidite design. This is
extremely attractive from a synthetic standpoint as it could be easily incorporated during
solid-phase

synthesis,

replacing

the

nitrobenzyl

linker

in

hairpin

designs.

Circular

ruthenium-caged oligos could be synthesized as linear strands with the Ru-phosphoramidite
linker in the middle, and then cyclization could be mediated enzymatically by a ligase.
Alternatively, the Ru-phosphoramidite linker could be incorporated adjacent to the 3’ end and the
oligo could by cyclized by a 3′ azide / 5′ alkyne intramolecular click, which we have performed
nearly quantitatively without need for further purification (Yang et al., 2018). However,
coordinating ligands containing the diisopropyl amine- and cyanoethyl-protected phosphorus as
well as the trityl-protected hydroxyl groups in the correct stoichiometry to a Ru(II) polypyridyl
complex is no easy task, and such a synthesis must be performed at a suitably large scale for
addition in excess during solid-phase synthesis.
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Figure 5.1: Circular caging scheme with RuBEP.
Reproduced from Ruble et al. J. Inorg. Biochem. 2015 Sep;150:182-8
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Figure 5.2: Structural diagram of Ru-TIVA v1.
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Figure 5.3: Structural diagram of Ru-TIVA v2.
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Figure 5.4: Structural diagram of Ru-TIVA v3.
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Figure 5.5: RP-HPLC purification of linear bis-amino Ru-TIVA v1 after solid-phase synthesis and cleavage.
Purification was performed on a C18 column in a gradient of 0.1 M TEAA in increasing acetonitrile, with the
product eluting at ~37 min.
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Figure 5.6: RP-HPLC verification of azide-labeling for Ru-TIVA v1 after solid-phase synthesis and cleavage.
Purification was performed on a C18 column in a gradient of 0.1 M TEAA in increasing acetonitrile, with the
product eluting at ~29 min.
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Figure 5.7: RP-HPLC purification of clicked Ru-TIVA v1. Purification was performed on a C18 column in a
gradient of 0.1 M TEAA in increasing acetonitrile, with the product eluting at ~24 min.
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Figure 5.8: FRET emission of Ru-TIVA v1 upon 645 nm excitation. Circular Ru-TIVA alone in buffer
generates 90% FRET (red), after uncaging FRET decreases to 38% (orange), and after photolyzed TIVA is
bound to 30mer poly(A) RNA it drops further to 23% (green).
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Figure 5.9: Native gel-shift assay for linear bis-azide (lane 1), clicked circular Ru-TIVA (lane 2), clicked
circular Ru-TIVA + 30mer poly(A) RNA (lane 3), photolyzed Ru-TIVA (lane 4), photolyzed Ru-TIVA + 30mer
poly(A) RNA (lane 5), linear bis-azide + 30mer poly(A) RNA (lane 6). Cy3 (green) and Cy5 (red) were
directly excited and imaged, non-fluorescent 30mer poly(A) RNA was not directly imaged.
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Figure 5.10: RP-HPLC purification of linear bis-amino Ru-TIVA v2 after solid-phase synthesis and cleavage.
Purification was performed on a C18 column in a gradient of 0.1 M TEAA in increasing acetonitrile, with the
product eluting at ~19 min.
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Figure 5.11: (A) RP-HPLC verification of linear bis-azido Ru-TIVA v2 azide-labeling. Purification was
performed on a C18 column in a gradient of 0.1 M TEAA in increasing acetonitrile, with the product eluting at
~37 min.
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Figure 5.12: (A) RP-HPLC purification of clicked Ru-TIVA v2 after solid-phase synthesis and cleavage.
Purification was performed on a C18 column in a gradient of 0.1 M TEAA in increasing acetonitrile, with the
product eluting at ~25 min.
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Figure 5.13: (A) ESI-MS analysis of Ru-TIVA v2. ESI-MS verified the product mass (12,037 Da predicted,
12,040 Da observed). (B) FRET analysis of 18/7/7 +(D-Arg)9 TIVA probe in 1x STE buffer with or without
photoactivation (“+Light”, “-Light”) and with or without 1 eq. of a 30mer poly(A) RNA (“+Poly(A)”, “-Poly(A)”).
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Figure 5.14: Delivery of Ru-TIVA v2 into hippocampal tissue using PepFect6 carrier. A target cell (yellow
box) was photoactivated using 2-P 713 nm light, with Cy5 (top) and Cy5.5 FRET (bottom) signals collected
before (left) and after (right) photolysis. Accompanying plot shows relative change in intensities for Cy5 and
Cy5.5 FRET before (1-3 time points) and after (4-6 time point) uncaging.
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Figure 5.15: (A) Nanochip capillary electropherogram traces for (A) GFP-Poly(A) “input” RNA transcript
measured directly without pull-down, (B) GFP-Poly(A) transcript pulled down with unactivated Ru-TIVA v2,
and (C) GFP-Poly(A) transcript pulled down with activated Ru-TIVA v2.
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Figure 5.16: RP-HPLC separation of linear bis-amino Ru-TIVA v3 crude. Purification was performed on a
C18 column in a gradient of 0.1 M TEAA in increasing acetonitrile, with the product eluting at ~27 min.
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Figure 5.17: RP-HPLC separation of linear bis-azido Ru-TIVA v3. Purification was performed on a C18
column in a gradient of 0.1 M TEAA in increasing acetonitrile, with the product eluting at ~30 min.
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Figure 5.18: RP-HPLC separation of Ru-TIVA v3 bis-click reaction. Successfully circularized product was
isolated from a right shoulder at ~27 min. Purification was performed on a C18 column in a gradient of 0.1 M
TEAA in increasing acetonitrile.
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Figure 5.19: ESI-MS analysis of Ru-TIVA v3, with a principal mass of 11,444.6 Da (calculated 11,442.6 Da).
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Conclusions & Future Directions
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When I joined the TIVA project in 2013 everything seemed neatly worked out! It was
demonstrated that first-generation TIVA probe underwent (D-Arg)9-mediated delivery into a
variety of common cell types, remained stable in cells for ~8 h, pulled down minimal material prior
to photolysis, and generated a high-quality transcriptome upon activation and extraction. While
TIVA has continued to work in most respects for its original application, attempting to make TIVA
live up to its potential as a transformative, widely-adopted technology has been a humbling
experience. In the process of attempting to adapt such a complex method to a broad range of
biological applications we have needed to return to square one, re-examining everything we
thought we knew about how TIVA works. In the process of this re-examination, I have made
several accomplishments:
In Chapter 2 I presented measures taken to address inadvertent hydrolysis and
photolysis during TIVA synthesis, which led to marked improvements in TIVA synthesis,
producing reliably improved yields and purity. Additionally, TIVA storage in STE buffer and
subsequent shelf-life analyses led to storage improvements where TIVA could be safely stored for
roughly one year rather than 1-2 months. The worldwide collaborations that first-gen TIVA
sparked were a strong indicator for TIVA’s unique potential. In supporting these collaborations I
gained an appreciation for the complexity of the TIVA protocol and the difficulty involved in
applying the method to labs with new experimental systems. In particular, many labs wished to
apply TIVA to living model organisms, necessitating probes that were more nuclease resistant,
better caged.
In Chapter 3 I explored strategies for extending the life of TIVA probe in chick embryos,
starting with minor duplex extensions and eventually moving to a fully phosphorothioated probe
(PS-22/9/9 TIVA). PS-22/9/9 TIVA was found to have dramatically improved stability in serum (2-4
h → 24+ h) via benchtop FRET and polyacrylamide gel analyses, and the phosphorothioation
was also able to mediate uptake into fibroblasts based upon the adsorption of serum proteins. In
moving from benchtop assays to chick embryos, PS-22/9/9 TIVA retained its robust nuclease
resistance and remained intact with high FRET for 24+ h. However, TIVA studies were still limited
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by the cytosolic availability of PS-22/9/9 TIVA, which became more punctate, likely trapped within
endosomes, after 4.5 h. Additionally, although complete phosphorothioation rendered the probe
highly nuclease-resistant, the binding penalty it imparted upon the hairpin duplex was significant,
and the Kulesa lab reported background reads from unactivated TIVA samples.
In Chapter 4 I sought to address the background signal observed by the Kulesa lab and
others by improving the inertness of the TIVA hairpin in the presence of poly(A) RNA. After
addition of a terminal GC pair (22/9/9 GC TIVA) reduced the FRET perturbation imposed by
poly(A) RNA upon caged TIVA, I designed a probe with additional modifications including a
second terminal GC pair, a (PEG)3 spacer to relax the hairpin turn, and a modified blocking strand
configuration. The reinforced probe, 22/12/8 (GC)2 +(D-Arg)9 TIVA, showed no significant change
in pre-photolysis FRET when incubated with 1 eq of poly(A) RNA, resisted co-migration with
poly(A) RNA on native polyacrylamide gels, and did not pull down a significant amount of a
GFP-Poly(A) transcript or fibroblast lysate until after photolysis with 410 nm light.
In Chapter 5 I aimed to move away from 1-P 410 nm light altogether, instead adopting
2-P 713 nm light as a trigger for a RuBEP-cyclized TIVA probe. An early version of the probe
(Ru-TIVA v1) was efficiently synthesized and circularized, but was inadvertently photoactivated by
543 nm scanning of the Cy3 fluorophore. A subsequent redesign (Ru-TIVA v2) shifted the
reporter pair to Cy5-Cy5.5, adding a stem to space out the fluorophores post-photolysis, to
template the click reaction, and to extend the capture strand. While Ru-TIVA v2 could be
delivered into hippocampal tissue and selectively photoactivated with 2-P 713 nm light, the stem
was ultimately too labile: in vitro pull-down of a GFP-poly(A) transcript was demonstrated both
with and without photolysis. To correct this, I designed a third version (Ru-TIVA v3) with a less
accessible loop and a more stable stem flanked by the same GC:GC pair that had so effectively
aligned the 22/12/8 (GC)2 probe. Synthesis of this third version was accomplished, but with low
yields due to batch-specific cyanoethyl capping of the amino-modifiers needed for bis-click
circularization and the lack of differences in secondary structure between clicked and unclicked
material to exploit for purification.
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In summary, I have produced TIVA probes with either improved nuclease-resistance,
caging integrity, or 2-P near-IR light response. However, many of these improvements came with
their own costs ‒ phosphorothioated and circular RuBEP-linked designs had trade-offs of poorer
caging integrity and potentially more challenging synthesis. The best-caged probe, 22/12/8 (GC)2
+(D-Arg)9 TIVA, lacked the nuclease-resistance or 2-P near-IR activation profile of the other
probes. Incorporating all three of these advancements into one probe design that can still be
synthesized in useful yields with high purity will be a challenging undertaking. The most plausible
way that this could be accomplished would be to take the design of 22/12/8 (GC)2 TIVA, replace
the poly(U)/poly(A) strands with LNA or PNA, and replace the o-nitrobenzyl caging groups with
phosphoramidite-incorporated Ru(II) polypyridyl linkers. Due to the yield hit associated with
(D-Arg)9 conjugation (50-70%) as well as the generally poor cytosolic delivery it has provided in
our hands, the (D-Arg)9 would be omitted. Instead, lipid or polymeric nanoparticles could be
employed for delivery, simplifying probe synthesis while also providing additional insulation
against

nucleases

during

delivery.

This

approach

has

the

potential

to

integrate

nuclease-resistance, robust caging, and 2-P near-IR activation together, while being synthesized
in higher yields than first-gen (Arg)9-conjugated TIVA.

Cytosolic delivery and aggregation
While combining the previously discussed advancements into one probe is an important
long-term goal, optimization of TIVA delivery into the cellular cytosol remains a significant and
immediate hurdle to overcome. Several collaborators have had difficulty labeling their cells of
interest with TIVA, with a minority having success using the attached (D-Arg)9 CPP or with
electroporation. For several years we believed that we were observing successful delivery of
various TIVA probes into cultured fibroblasts based upon interior Cy5-FRET labeling and
subsequent loss of FRET after 405 nm activation. However, once we attempted to pull down the
mRNA from fibroblasts ‒ unsuccessfully ‒ it seemed that TIVA probe was internalized but not

153

available in the cytosol. Collaborations with the Kulesa lab (Chapter 3) indicated that
electroporation was largely more successful at delivering TIVA to the cytosol while keeping it
evenly distributed. Conversely, experiments with (D-Arg)9 were more likely to end up with
punctate signal earlier in the experiment. It is worth noting that (D-Arg)9-mediated delivery works
well in the hands of the Eberwine lab, possibly due to a unique compatibility with neuronal cell
membrane compositions or enhanced permeability of the cells due to transient mechanical
perturbations imparted during tissue sectioning. For many researchers, though, 22/9/9 (GC)2 TIVA
without (D-Arg)9 may become the probe of choice. Still, electroporation has its own risks,
including substantial cell death, and may not be applicable to many experimental systems.
Therefore, future research must focus on evaluating alternative delivery strategies that can
broadly deliver TIVA into a variety of cells in complex tissue samples. Fortunately, there are
thousands of commercially available delivery peptides, lipid nanoplexes, polymer polyplexes, as
well as cell-type-specific ligands to explore. This challenge is not unique to TIVA and
oligonucleotide delivery is a rapidly progressing field.
Probe quaternary structure ‒ namely aggregation between probes ‒ is another important
facet that is poorly understood and intimately related to delivery. The combination of TIVA hairpin
concatenation as well as the ionic intermolecular attraction between one probe’s cationic CPP
and another probe’s anionic backbone create potential for tenacious aggregation that is difficult to
correct by traditional heat-denaturation protocols. TIVA probe appears to be most vulnerable to
aggregation when appended with (D-Arg)9 and concentrated above ~400 μM, especially at
temperatures above 30 °C. For this reason, great care is taken during probe synthesis to keep
TIVA around 100-200 μM and at rt, and CPP-appended TIVA is stored and shipped in buffer
rather than dried. It is possible that minor variations in probe preparation as well as structural
differences between probe designs lead to important functional differences in quaternary
structure. Endocytosis is most successfully triggered by nanoparticles ≤100 nm in size, for
example (El-Sayed and Harashima, 2013). Additionally, the surface charge of the probe may also
play an important role in TIVA uptake and trafficking. Typically, we envision (D-Arg)9-conjugated
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TIVA as a nanoparticle with its positive CPPs presented to the exterior to mediate cell uptake.
However, Chad Mirkin has challenged this view with his introduction of Spherical Nucleic Acids
(Barnaby et al., 2016; Cutler et al., 2012), which can contain a positively charged core and a high
exterior-density of negatively charged oligos. Surprisingly, this surface presentation of dense
negative oligos mediates cell uptake, and it is possible that multiple (D-Arg)9-appended TIVA
probes could form a nanoparticle with a similar conformation. Preliminary zetasizer analysis of
22/9/9 (GC)2 suggests that the probe has a strongly negative surface charge in solution. Further
DLS experiments would aid in characterizing probe quaternary structure. To accomplish this, TIVA
probes without Cy5 would need to be synthesized, as the fluorophore interferes with light typically
used for DLS. Better understanding the quaternary structure and surface charge of TIVA could
guide our design of future probes, leading to improvements in delivery and mRNA capture.

TIVA loading effects
Even with an infallibly caged probe, there are additional sources of potential background
or sequencing contamination that warrant consideration and further study. Little is currently
known about the quantity of TIVA reaching the cell cytosol in a typical experiment. Capturing
low-abundance transcripts motivates the use of larger amounts of TIVA in cellular experiments.
However, overloading a cell with excess TIVA could have a number of serious consequences. In
a simple thought experiment, a tissue slice is oversaturated with TIVA such that every cell
receives twice the amount of TIVA relative to the amount of mRNA that could be bound. After
photolysis of the single target cell, patch-pipette extraction of that cell frequently involves
capturing a margin of neighboring unactivated cells, or at least fractions of neighboring cells. If
that one target cell, containing a significant excess of photoactivated-yet-unbound TIVA, were
lysed in conjunction with unactivated cells, it seems reasonable that the excess photoactivated
TIVA from the target cell could bind to lysate from neighboring cells, resulting in background
signal that dilutes the target reads. In another possible scenario, TIVA is loaded into an embryo,
again reaching cells in excess. TIVA is then photoactivated in a cell, perhaps at a specific
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developmental milestone. If the cell is not collected and lysed immediately ‒ say, the researcher
wished to track the photoactivated cell’s fate in a downstream developmental process ‒ the
quality of the transcriptome might suffer. At best, newly-synthesized mRNA would be captured by
the remaining photoactivated-yet-unbound TIVA and the resulting sequencing would offer a
survey of genes natively expressed by that cell, but with poor temporal resolution. At worst,
however, the complete binding of the cell’s poly(A) tails by a foreign oligo would impart a
perturbative effect on the cell. While the portion of the transcriptome captured at the time of
photolysis might be authentic, mRNA captured downstream from this perturbation would be of
questionable quality, potentially tainting the sequencing results.
How likely is it that we are delivering TIVA in excess? A cell containing 200,000
transcripts, each with 200 nt poly(A) tails, would have 40 x106 adenine bases available for
binding, ignoring any other poly(A) stretches in the cell. A TIVA probe with a 22mer poly(U)
capture strand would require ~1.8 x106 copies (or 3.0 amol) to effectively saturate those tails. In
the fibroblast control experiments performed for Chapter 4, roughly 1 million cells in a 2 cm2 well
were incubated with 1.0 μM TIVA, 200 x 106 amol of TIVA in total. With 200 amol of TIVA
available per cell, only 1.5% of the TIVA in solution would need to reach each cell cytosol to
achieve saturation. Reaching 1.5% delivery of TIVA in solution to these cells seems like a low bar,
but the majority of oligonucleotide probes fail to make it to the cytosol, either remaining in solution
or becoming trapped and degraded in endosomal compartments (Juliano, 2016). Uptake of
104-105 antisense strands into cell cytosol is considered feasible (Roth, 2005; Wu-Pong, 1996;
Yakubov et al., 1989), but TIVA saturation would require at least an order of magnitude higher
uptake. In summary, given the amount of TIVA involved in an experiment, oversaturation seems
possible. However, the maximum amount of TIVA that can make it into the cytosol is still
unknown, and must be experimentally verified. As a start, it may be possible to use the number of
reads collected from a sequencing experiment to loosely estimate the amount of TIVA involved.
For quantitative measurements within the cell, Fluorescence Correlation Spectroscopy (FCS)
could be employed, utilizing the time-dependent fluorescence fluctuations of TIVA passing
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through a small focal volume to calculate its absolute concentration within a cell (LaRochelle et
al., 2015). Deconvoluting cytosolic concentration from endosomal concentration is more difficult ‒
the Schepartz lab approximated this by performing measurements in regions of even rather than
punctate signal. With a more robust method of assessing intracellular TIVA concentration, cells
that are oversaturated could be screened out as photolysis candidates.

Closing remarks
Despite the challenges in pushing TIVA forward, it is clear from discussions with
biological researchers that TIVA is still poised to answer important questions that no other method
can. As we move into the future, the TIVA project will continue to explore ways to maintain greater
probe stability in deeper tissue regions of more complex biological models, using progressively
longer wavelengths of light for activation. Perhaps in the not-so-distant future we will see a
peptide nucleic acid TIVA probe caged with a phosphoramidite-incorporated Ru(II) polypyridyl
linker being photoactivated by 2-P 900 nm light within the tumor of a clinical patient, with the
resulting transcriptomic profile utilized to guide their personalized treatment.
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